書籍詳細

1. 卵巣癌の歴史に学ぶ ―樋口一成・加藤俊両先生に捧ぐ―

P.9 掲載の参考文献

• 1) 加藤俊, 寺島芳輝:卵巣. 現代産科婦人科学大系第 8巻B1女性性器の肥大, 萎縮・腫瘍, pp. 119-319, 中山書店, 東京, 1973.

• 2) 名取禮二:樋口一成伝. pp. 13-179, 学校法人東京慈恵会医科大学, 東京, 1976.

• 3) 日本産科婦人科学会・日本病理学会編:卵巣腫瘍取扱い規約第1部組織分類ならびにカラーアトラス. pp. 1-51, 金原出版, 東京, 1990.

• 4) 寺島芳輝, 安田允, 森本紀:Agingと卵巣腫瘍. 産婦人科の実際26:605-610, 1977.

• 5) 佐藤勝彦監修:みるみる理解できる相対性理論. Newton別冊(7月):相対性理論発表100周年記念, pp. 18-20, pp. 54-151, 2005

2. 疫学

P.16 掲載の参考文献

• 1) Coleman MP, Esteve J, Damiecki P, et al:Trends in cancer incidence and mortality. IARC Sci Publ 1-806, 1993.
  pubmed

• 2) Tominaga S, Kuroishi T, Aoki K:Cancer mortality statistics in 33 countries 1953-1992. 76, Roppo Shuppan, Nagoya. 1998.

• 3) Whittemore AS, Harris R, Itnyre J:Characteristics relating to ovarian cancer risk:collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136:1184-1203, 1992.

• 4) Hankinson SE, Hunter DJ, Colditz GA, et al:Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270:2813-2818, 1993.
  pubmed

• 5) Rebbeck TR, Lynch HT, Neuhausen SL, et al:Prophylactic oophorectomy in carriers of BRCAI or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002.
  pubmed

• 6) Cramer DW, Hutchison GB, Welch WR, et al:Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 71:711-716, 1983.

• 7) Stratton JF, Pharoah P, Smith SK, et al:A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105:493-499, 1998.
  pubmed

• 8) Garg PP, Kerlikowske K, Subak L, et al:Hormone replacement therapy and the risk of epithelial ovarian carcinoma:a meta-analysis. Obstet Gynecol 92:472-479, 1998.
  pubmed

• 9) Anderson GL, Judd HL, Kaunitz AM, et al:Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures:the Women's Health Initiative randomized trial. JAMA 290:1739-1748, 2003.
  pubmed

• 10) Koch M, Gaedke H, Jenkins H:Family history of ovarian cancer patients:a case-control study. Int J Epidemiol 18:782-785, 1989.
  pubmed

• 11) Whittemore AS, Wu ML, Paffenbarger RS Jr, et al:Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 128:1228-1240, 1988.
  pubmed

• 12) Harlow BL, Cramer DW, Bell DA, et al:Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 80:19-26, 1992.

• 13) Calle EE, Rodriguez C, Walker-Thurmond K, et al:Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638, 2003.

• 14) Schouten LJ, Goldbohm RA, van den Brandt PA:Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol 157:424-433, 2003.
  pubmed

• 15) Engeland A, Tretli S, Bjソrge T:Height, body mass index, and ovarian cancer:a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 95:1244-1248, 2003.

• 16) Brinton LA, Gridley G, Persson I, et al:Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176:572-579, 1997.
  pubmed

P.22 掲載の参考文献

• 1) Lynch HT, Krush AJ:Cancer family "G"revisited 1895-1970. Cancer 27:1505-1519, 1971.
  pubmed

• 2) Li FP, Fraumeni JF Jr:Soft tissue sarcomas, breast cancer and other neoplasma:A familial syndrome? Ann Intern Med 71:745-775, 1969.

• 3) Markin D, Friend SH, et al:Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1209, 1990.

• 4) Ogawa H, Kato I, et al:Family history of cancer among cancer patients. Jpn J Cancer Res 76:113-118, 1985.
  pubmed

• 5) Lee WH, Bookstein R, et al:Human retinoblastoma susceptibility gene:Cloning, identification and sequence. Science 235:1349-1399, 1987.

• 6) Fishel R, Lescoe MK, et al:The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1037, 1993.
  pubmed

• 7) Narod SA, Madlensky L, Bradley L, et al:Hereditary and familial ovarian cancer in southern Ontario. Cancer 74:2341-2346, 1994.
  pubmed

• 8) Piver MS:Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 85:9-17, 2002.
  pubmed

• 9) Miki Y, Swenson J, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRCAl. Science 266:66-71, 1994.

• 10) Wooster R, Bignell G, et al:Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995.
  pubmed

• 11) Matsushima M, Kobayashi K, Emi M, et al:Mutational analysis of the BRCAI gene in 76 Japanese ovarian cancer patients:four germ line mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953-1956, 1995.

• 12) Aida H, Takakuwa K, Nagata H, et al:Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCAl. Clin Cancer Res 4:235-240, 1998.

• 13) Sekine M, Nagata H, Tsuji S, et al:Mutational analysis of BRCAI and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 0varian cancer families:two common founder mutations of BRCAl in Japanese population. Clin Cancer Res 7:3144-3150, 2001.

• 14) Struewing JP, Hartge P, Wacholder S, et al:The risk of cancer associated with specific mutations of BRCAl and BRCA2 among Ashkenazi Jews. N Engl J Med 326:1401-1408, 1997.

• 15) Claus EB, Schiidkraut JM, Thompson WD, et al:Attributable risk of breast and ovarian cancer. Cancer 77:2318-2324, 1996.

• 16) Whittemore AS, Gong G, Itnyre J:Prevalence and contribution of BRCAl mutations in breast cancer and ovarian cancer; results from three U. S. population-based case-control studies of ovarian canceer. Am J Hum Genet 60:496-504, 1997.

• 17) Chen Y, Lee WH, Chew HK:Emerging roles of BRCA I in transcriptional regulation and DNA repair. J Cell Physiol 181:385-392, 1999.

• 18) Goldgar D, Stratton MR:Inherited Tumour Syndromes. In "WHO classification of tumours. Pathology & Genetics. Tumours of the breast and female genital organs". Ed. by Tavassoli FA, Devilee P. pp336-363, IARC press, 2003.

• 19) Berchuck A, et al:Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4:2433-2437, 1998.
  pubmed

• 20) Pharoah PD, et al:Survival in familial BRCA1 associated, and BRCA2 associated epithelial ovarian cancer. Cancer Res 59:868-871, 1999.
  pubmed

• 21) Narod SA, et al:0ral contraceptives and the risk of hereditary ovarian cancers. Hereditary ovarian cancer clinical study group. N Engl J Med 339:424-428, 1998.

• 22) Vasen HF, et al:IGC-HNPCC:New clinical criteria for hereditary nonpolyposis colorectal cancer(HNPCC, Lynch syndrome) proposed by the International collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999.

• 23) Schwartz MD, Kaufman E, Peshkin BN, et al:Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21:4034-4041, 2003.
  pubmed

• 24) King MC, Marks JH, Mandell JB:New York Breas Cancer Study Group:Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003.

• 25) Modugno F, Ovarian Cancer and High-Risk Women Symposium Presenters:Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol 0ncol 91:15-31, 2003.
  pubmed

• 26) Kashima K, Oite T, Aoki Y, et al:Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res 91:399-409, 2000.

• 27) Berchuck A, Heron KA, Carney ME, et al:Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4:2433-2437, 1998.
  pubmed

• 28) Shibuya S, Aoki Y, Aida H, et al:Mutational analysis of the BRCA1 gene in sporadic ovarian cancer in Japan. Int J Clin Oncol 4:3 48-352, 1999.

3. 診断

P.38 掲載の参考文献

• 1) 秦 菅吉, 宮崎康二:卵巣腫瘍の画像診断. 産婦人科治療80:416-423, 2000.

• 2) 山内英明:卵巣腫瘍の集団検診. 卵巣腫瘍のマネージメント(河野.郎編). pp100-104, 永井書店, 大阪, 1994.

• 3) 日本超音波医学会用語診断基準委員会:卵巣腫瘍のエコーパターン分類の公示について. 超音波医学 27:912-914, 2000.

P.54 掲載の参考文献

• 1) 小西郁生:卵巣の腫瘍. 日本産科婦人科学会編. 産婦人科研修の必修知識, pp529-533, 日本産科婦人科学会, 東京, 2004.

• 2) 小西郁生, 伊東和子:卵巣腫瘍. 神崎秀陽編. 看護のための最新医学講座16婦人科疾患, pp262-280, 中山書店, 東京, 2001.

• 3) 小西郁生:卵巣腫瘍-良・悪性鑑別の要点MRI検査法. 臨床婦人科産科46:33-35, 1992.

• 4) 松尾義朋, 田村綾子, 中園貴彦:婦人科がん画像診断の最先端. 卵巣表層上皮性腫瘍. 産婦人科の実際 54:1529-1538, 2005.

• 5) 富樫かおり:卵巣癌組織型の推定. 臨床婦人科産科 56:652-657, 2002.

• 6) 加藤 清, 鈴木昭久, 伊東和子, ほか:結腸癌の卵巣転移は原発性卵巣癌に類似した多嚢胞性腫瘤を形成しうる. 日産婦関東連合会報37:73-81, 2000.

• 7) 小西郁生, 富樫かおり:子宮内膜症性嚢胞より発生する卵巣癌の早期診断. 子宮内膜症の診断と治療, pp104-118, 真興交易医書出版, 東京, 1997.

• 8) Komatsu T, Konishi I, Mandai M, et al:Adenexal masses:comparison of transvagainal US and Gadolinium-enhanced MR imaging:assessment of intratumoral structure. Radiology 198:109-115, 1996.

• 9) 今岡いずみ, 林 貴史, 松尾導昌, ほか:婦人科がん画像診断の最先端, 卵巣胚細胞腫瘍. 産婦人科の実際54:1549-1558, 2005

P.60 掲載の参考文献

• 1) 松岡昭治:コンピューター断層撮影(CT). 放射線医学大系25B, 高橋信次, 吉利和編, pp119-133, 中山書店, 東京, 1987.

• 2) 石田 修, 浜田辰巳:卵巣, 全身のCT. 高橋睦正 編, pp582-602, 南江堂, 東京, 1991.

• 3) 井筒俊彦, 中田尋晶, 須藤ちず子:卵巣良性腫瘍・類腫瘍性疾患. 新女性医学大系36巻, 薬師寺道明 編, pp206-224, 中山書店, 東京, 2000.

• 4) 中田さくら, 宇田川康博, 野澤志朗:卵巣癌. 新女性医学大系36巻, 薬師寺道明編, pp225-240, 中川書店, 東京, 2000.

• 5) 今岡いずみ, 林 貴史, 松尾導昌, ほか:婦人科がん画像診断の最先端-卵巣胚細胞腫瘍. 産婦の実際54:1549-1558, 2005.

• 6) 三森天人, 上者郁夫, 浅川 徹, ほか:婦人科がん画像診断の最先端-卵巣性索間質性腫瘍. 産婦の実際54:1539-1548, 2005.

P.66 掲載の参考文献

• 1) Abdul-Karim FW, . Kida M, Wentz WB, et al:Bone metastasis from gynecologic carcinomas:a clinicopathologic study. Gynecol Oncol 39:108-114, 1990.
  pubmed

• 2) Kurokawa T, Yoshida Y, Kawahara K, et al:Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:926-932, 2004.
  pubmed

• 3) Fenchel S, Grab D, Nuessle K, et al:A symptomatic adnexal masses:correlation of FDG PET and histopathologic findings. Radiology 223:780-788, 2002.

• 4) Nakamoto Y, Saga T, Fujii S:Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer 15:701-709, 2005.
  pubmed

• 5) Nishizawa S, Inubushi M, Okada H:Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 32:549-556, 2005.
  pubmed

• 6) Cormio G, Rossi C, Cazzolla A, et al:Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 13:125-129, 2003.
  pubmed

P.71 掲載の参考文献

• 1) 宮地 徹, 森脇昭介, 桜井幹己:産婦人科病理学診断図譜 第3版, 杏林書院, 東京, 1998.

• 2) 和泉 滋, 新井広冶, 沼田ますみ:卵巣腫瘍の細胞診. 新女性医学大系40巻婦人科腫瘍の細胞診 第1版(野澤志朗編), pp266-285, 中川書店, 東京, 1999.

• 3) 野田起一郎, 伊藤耕造:細胞学的診断. 図説臨床 [癌]シリーズNo. 23卵巣腫瘍・睾丸腫瘍(末舛恵一, 加藤 俊, 吉田 修編), pp40-46, メジカルビュー社, 東京, 1988.

• 4) 落合和彦, 石塚康夫:卵巣:術中細胞診とステージング. 臨検44:1351-1353, 2000.

• 5) 亀井敏昭, 岡村 宏, 渋田秀美, ほか:中皮細胞の見方. Med Technol 31:588-594, 2003.
  Medical*Online

• 6) 西田正人, 蔵本博行, 巽英樹, ほか:卵巣clear cell carcinomaの腹水細胞所見-Mirror ball patternの提唱とその成因-. 日臨細胞会誌18:280-287, 1979.

• 7) 山辺 徹:卵巣腫瘍および卵管癌の細胞診. 図説産婦人科VIEW-2細胞診 読み方のコツと鑑別のポイント(山辺 徹, 野澤志朗編), pp126-141, メジカルビュー社, 東京, 1993.

P.78 掲載の参考文献

• 1) Waldmann TA, Herberman RB:Tumor markers in diagnosis and in monitoring therapy. IN:Cancer Medicine(ed. Holland JF and Frei E III). pp1O68-1089, Lea & Febiger, Philadelphia, 1982.

• 2) 大倉久直:腫瘍マーカーの臨床的意義. 病理と臨床 8:4-11, 1990.

• 3) Bast RC Jr, Feeney M, Lazarus H, et al:Reactivitv of amonoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337, 1992.

• 4) Yin BW, Dnistrian A, Lloyd KO:Molecular cloning of the CA125 0varian cancer antigen. J Biol Chem 276:27371-27375, 2001.

• 5) Nozawa S, et al:Tumor-associated mucin-type glycoprotein(CA54/61) defined by two monoclonal antibodies(MA54 and MA61) in ovarian cancers. Cancer Res 49:493-498, 1989.
  pubmed

• 6) Colcher D, et al:A specyram of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78:6199-3203, 1981.

• 7) 野澤志郎, ほか:卵巣癌の新しい腫瘍マーカーCA54/61およびCA602の基礎的, 臨床的有用性の検討(第3報). 癌と化療19:823-832, 1994.

• 8) Solter D, et al:Monoclonal antibody defining a stage-specific embryonic antigen(SSEA-1). Proc Natl Acad Sci USA 75:5565-5569, 1978.
  pubmed

• 9) Gold P, Freedman SO:Demonstration of tumor specific antigen in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 121:439-462, 1965.
  pubmed

• 10) 大田順子, 深澤一雄, ほか:細胞骨格関連蛋白(加藤紘, 野澤志郎, 編), 図説産婦人科View18 「腫瘍マーカー」. pp120-127, メジカルビュー社, 東京, 1995.

• 11) Abelev GI, et al:Production of embryonal alpha-globurin by transplantable mouse hepatomas. Transplantation I:174-180, 1963.
  pubmed

• 12) National Institutes of Health Consensus Development Conference Statement:Ovarian cancer:screening, treatment, and follow-up. Gynecol Oncol 55:S4, 1994.
  pubmed

• 13) Jacobs IJ, Skates S, Davies AP, et al:Risk of diagnosis of ovarian cancer after rasied serum CA125 concentration:aprospective cohort study. BMJ 313:1355-1358, 1996.

• 14) Patrick T, Susan G, Arbuck EA, et al:New guidelines to evaluation the response to treatment in solid Tumor. J Natl Cancer Inst 92:205-216, 2000.

• 15) 日本婦人科腫瘍学会(編):卵巣がん治療ガイドライン2004年版, pp42-43, 金原出版, 東京, 2004.

• 16) L Shi:Biomimeric surfaces of Biomaterials using mucin-type glycoproteins. Trends Glycosci Glycotech 12:229-239, 2000.

P.86 掲載の参考文献

• 1) 日本婦人科腫瘍学会編:卵巣がん治療ガイドライン. 金原出版, 東京, 2004.

P.91 掲載の参考文献

• 1) Iba T, Kigawa J, Kanamori Y, et al:Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 95:418-423, 2004.

• 2) Fujita M, Enomoto T, Murata Y:Genetic alterations in ovarian carcinoma:with specific reference to histological subtypes. Mol Cell Endocrinol 202:97-99, 2003.
  pubmed

• 3) Bookman MA, Darcy KM, Clarke-Pearson D, et al:Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:aphase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-290, 2003.

• 4) King MC, Marks JH, Mandell JB:Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646, 2003.
  pubmed

• 5) Kigawa J, Sato S, Shimada M, et al:p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 14:165-171, 2001.
  pubmed

• 6) Sato N, Tsunoda H, Nishida M, et al:Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary:possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052-7056, 2000.
  pubmed

• 7) Kigawa J, Minagawa Y, Cheng X, et al:Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 4, 1737-1741, 1998.
  pubmed

• 8) International Human Genome Sequencing Consortium:Finishing the euchromatic sequence of the human genome. Nature 431:931-945, 2004.

• 9) The International HapMap Consortium:A haplotype map of the human genome. Nature 437:1299-1320, 2005.

• 10) Spurdle AB, Webb PM, Purdie DM, et al:Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci:risk of ovarian cancer by histological subtype. Carcinogenesis 22:67-72, 2001.
  pubmed

• 11) Ono K, Tanaka T, Tsunoda T, et al:Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60:5007-5011, 2000.
  pubmed

• 12) Hartmann LC, Lu KH, Linette GP, et al:Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11:2149-2155, 2005.
  pubmed

P.94 掲載の参考文献

• 1) Goff BA, Mandel L, Muntz HG, et al:Ovarian carcinoma diagnosis:Results of national ovarian cancer survey. Cancer 89:2068-2075, 2000.
  pubmed

• 2) Vine MF, Ness RB, Calingaert B, et al:Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 83:466-471, 2001.
  pubmed

• 3) Olson SH, Mignone L, Nakraseive C, et al:Symptoms of ovarian cancer. Obstet Gynecol 98:212-217, 2001.
  pubmed

• 4) Vine MF, Calingaert B, Berchuck A, et al:Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol 0ncol 90:75-82, 2003.
  pubmed

• 5) Chan YM, Ng TY, Lee PWH, et al:Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer. Gynecol Oncol 90:651-656, 2003.
  pubmed

• 6) Smith EM, Anderson B:The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 56:2727-2732, 1985.
  pubmed

• 7) Barber HRK, Graber EA:The PMPO syndrome. Obstet Gynecol 38:921-923, 1971.

• 8) Portenoy RK, Kornblith AB, Wong G, et al:Pain in ovarian cancer patients:Prevalence, characteristics, and associated symptoms. Cancer 74:907-915, 1994.
  pubmed

• 9) 鈴木光明, 関口 勲, 玉出太朗:上皮性卵巣腫瘍お よび類皮嚢胞腫におけるエストロゲン産生能. 日産婦誌38:303-310, 1986.

• 10) Sekiguchi I, Suzuki M, Tamada T:Estrogen producing activity in epithelial ovarian tumors and dermoid cysts. Asia-Oceania J Obstet Gynaecol 15:367-374, 1989.
  pubmed

• 11) Smith LH, Morris CR, Yasmeen S, et al:Ovarian cancer:Can we make the clinical diagnosis earlier? Cancer 1O4:1398-1407, 2005.

4. 病理

P.100 掲載の参考文献

• 1) 笹野公伸, 森谷卓也, 真鍋俊明(編):臨床医・初期研修医のための病理検査室利用ガイド. 病理検査の依頼からCPCレポートの作成まで. 文光堂, 東京, 2004.

• 2) 森谷卓也:病理学的マネージメント. 卵巣腫瘍のマネージメント(河野一郎編). pp 171-194, 永井書店, 大阪, 1994.

• 3) 手島伸一:卵巣腫瘍の取り扱いと肉眼観察の要点. pp25-28, 文光堂, 東京, 2004.

• 4) 真鍋俊明:外科病理診断学. 病理組織診断のつけ方, 考え方. 金芳堂, 京都, 1998.

• 5) 長村義之:外科病理マニュアル第二版. 文光堂, 東京, 1996.

• 6) 日本産科婦人科学会, 日本病理学会(編):卵巣腫瘍取扱い規約. 第1部 組織分類並びにカラーアトラス. 金原出版, 東京, 1990.

P.106 掲載の参考文献

• 1) Clement PB:Tumor-like Lesions of the ovary associated with pewgmancy. Int J Gynecol Pathol 12:108-115, 1993.
  pubmed

• 2) Wajda KJ, Lucas JG, Marsh WLJr:Hyperreactio luteinalis:benign disorder masquerading as an ovarian neoplasm. Arch Pathol Lab Med 113:921-925, 1987.

• 3) 手島伸一, 本田律生, 片渕秀隆:卵巣子宮内膜症の成因と進展およびその病態, 病理と臨床 24:234-242, 2006
  Medical*Online

• 4) 小林 浩:長期間の疫学調査よりみた卵巣子宮内膜症の癌化について. 病理と臨床 23(印刷中).

• 5) 手島伸一:良性漿液性腫瘍. 卵巣腫瘍病理アトラス, 石倉 浩, 手島伸一:編, pp. 111-114, 文光堂, 東京, 2004.

• 6) 長坂徹郎:良性粘液性腫瘍. 卵巣腫瘍病理アトラス, 石倉 浩, 手島伸一:編, pp. 134-135, 文光堂, 東京, 2004.

• 7) Russell P, Farnsworth A:Thecoma-fibroma group of tumors. Surgical Pathology of the Ovaries. 2nd ed, Russell P and Fransworth eds, pp. 417-433, Churchill Livingstone, Edinburgh, 1997.

• 8) 本山悌一:境界悪性腫瘍の概念と診断の基礎. 病理と臨床 24:2-6, 2006.
  Medical*Online

• 9) 本山悌一:性索間質性腫瘍の病理-特に顆粒膜細胞腫とアンドロブラストーマー. 日婦腫瘍誌 17:104-108, 1999.

• 10) 本山悌一:セルトリ.問質細胞腫瘍. 卵巣腫瘍病理アトラス, 石倉 浩.手島伸一:編, pp. 205-209, 文光堂, 東京, 2004.

P.111 掲載の参考文献

• 1) Reya T, et al:Stem cell, Cancer and cancer stem cells. Nature 414:105-111, 2001,
  pubmed

• 2) Dick JE:Breast cancer stem cell revealed. Proc Natl Acad Sci USA 100:3457-3549, 2003.

• 3) 井上正樹:症例から学ぶ婦人科病理学入門. 産婦人科治療. 89:353-363, 2004.

• 4) Russell P, et al:Epithelial/stromal ovarian tumors. In ed:Robby SJ, et al, Pathology of the female reproductive tract. Churchill Livingstone, 2002.

• 5) Naora H, Montell DJ:Ovarian cancer metastasis:integrating insights from disparate model organisms. Nature Rev Cancer 5:355-366, 2005.

P.115 掲載の参考文献

• 1) 日本産科婦人科学会.日本病理学会編:卵巣腫瘍取扱い規約. I. 組織分類. 金原出版, 1990

• 2) Tavassoli FA and Devilee P.:Pathology and Genetics. Tumours of the Breast and Female Genitale Organs. World Health Organization Classification of Tumors, IARC Press, Lyon, 2003

• 3) Scully RE, Young RH, Clement PB. Tumors of the Ovary and Maldeveloped Gonads, Fallopian Tube and Broad Ligsament. AFIP, Washington, 1998

• 4) Kurman R. J. Blaustein's Pathology of the Female Genital Tract, 5th ed. Springer-Verlag, New York, 2002

• 5) Tateno H, Sasano N, Ovarian tumours in Sendai, Japan. General hospital material. in UICC Technical Report Series. Vol. 75. An international survey of distributions of histologic types of tumours of the testis and ovary. H Stlaberg, ed., Geneva, UICC, 1983:291-6

• 6) Nakashima N, Nagasaka T, Fukata S et al. Study of ovarian tumors treated at Nagoya University Hospital, 1965-1988. Gynecol 0ncol 1990; 37:103-11.
  pubmed

• 7) 10) Koonings PP, Campbell K, Mishell DR Jr, Grims DA. Relative frequency of primary ovarian neoplasms:A 10-year review. Obstet Gynecol 1989.

• 8) Heintz PA, Hacker NK, Lagasse LD. Epidemiology and etiology of ovarian cancer:a review. Obstet Gynecol 1985; 66:127-135.

• 9) 清川貴子. 臨床編:卵巣. 藤井信吾.寺島芳輝編. 図説婦人科view 25. 腫瘍. 臨床病理学. Medical view, 東京, 1996; 130-149

• 10) Austin RM, Norris HJ. Malignant Brenner tumor and transitional cell carcinoma of the ovary:a comparison. Int J Gynecol Pathol 1987; 6(1):29-39

• 11) Silva EG, Robey-Cafferty SS, Smith TL, Gershenson DM. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol 1990 Apr; 93(4):457-65.
  pubmed

• 12) Hollingsworth HC, Steinberg SM, Silverberg SG, Merino MJ. Advanced stage transitional cell carcinoma of the ovary. Hum Pathol. 1996 Dec; 27(12):1267-72

P.133 掲載の参考文献

• 1) 日本産科婦人科学会・日本病理学会編:卵巣腫瘍取扱い規約, 第1部, 組織分類ならびにカラーアトラス. 金原出版, 東京, 1990

• 2) Scully RE, Sobin LH, et al.:Histological Typing of Ovarian Tumours, World Health Organization International Histological Classification of Tumours, 2nd ed. . Springer, New York, 1999

• 3) Tavassoli FA, Mooney E, Gersell DJ, et al:Sex cord-stromal tumours. Tumours of the Breast and Female Genital Organs, Pathology & Genetics, World Health Organization Classification of Tumours, Tavassoli FA & Devilee P eds., 146-161, LARC Press, Lyon, 2003

• 4) Russell P, Robboy SJ, Anderson MC:Ovarian tumors:classification and clinical perspective. Pathology of the Female Reproductive Tract, Robboy SJ, Anderson MC and Russell P eds., 527-538, Churchill Livingstone, London, 2002

• 5) Clement PB, Young RH:Sex cord-stromal and steroid cell tumors. Atlas of Gynecologic Surgical Pathology, Clement PB and Young RH eds., 364-388, W. B. Saunders Company, Philadelphia, 2000

• 6) Roth LM:Recent advances in the pathology and classification of ovarian sex cord-stromal tumors. Int J Gynecol Pathol 25:199-215, 2006
  pubmed

• 7) DiSaia PJ, Creasman WT:Germ cell, stromal, and other ovarian tumors. Clinical Gynecologic Oncology, 6th ed., DiSaia PJ and Creasman WT eds., 351-375, Mosby, Inc., St Louis, 2002

• 8) 井上正樹:卵巣の疾患. 症例から学ぶ婦人科腫瘍学 入門, 井上正樹編, 155-228, 永井書店, 大阪, 2006

• 9) Nakashima N, Nagasaka T, Fukata S, et al:Study of ovarian tumors treated at Nagoya University Hospital, 1965-1988. Gynecol Oncol 37:103-111, 1990
  pubmed

• 10) 婦人科腫瘍委員会報告:1998年度, 1999年度卵巣悪性腫瘍. 日産婦誌54:736-792, 2002

• 11) 婦人科腫瘍委員会報告:2000年度卵巣腫瘍患者年報, 2001年度卵巣腫瘍患者年報. 日産婦誌56:35-58, 91-114, 2004

• 12) 婦人科腫瘍委員会報告:2002年度卵巣腫瘍患者年報. 日産婦誌57:1022-1045, 2005

• 13) 婦人科腫瘍委員会報告:2003年度卵巣腫瘍患者年報. 日産婦誌57:1744-1767, 2005

• 14) Russell P, Robboy SJ, Anderson MC:Sex cord-stromal and steroid cell tumors of the ovary. Pathology of the Female Reproductive Tract, Robboy SJ, Anderson MC and Russell P eds., 607-640, Churchill Livingstone, London, 2002

• 15) 山辺徹, 中島久良:ホルモン産生卵巣腫瘍. 卵巣-基礎と臨床-, 林基之,一戸喜兵衛, 鈴木秋悦編, 435-453, 金原出版, 東京, 1980

• 16) Young RH, Scully RE:Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 9:543-569, 1985
  pubmed

• 17) Hayes MC, Scully RE:Ovarian steroid cell tumors(not otherwise specified). A clinicopathological analysis of 63 cases. Am J Surg Pathol 11:835-845, 1987

• 18) Teilum G:Classification of endodermal sinus tumor(Mesoblastoma vitellium) and so-called "Embryonal carcinoma"of the ovary. Acta Pathol Microbiol Scand 64:407-429, 1965

• 19) Nogales F, Talerman A, Kubic-Huch RA et al.:Germ cell tumours. Tumours of the Breast and Female Genital Organs, Pathology & Genetics, World Health Organization Classification of Tumours, Tavassoli FA & Devilee P eds., 163-179, LARC Press, Lyon, 2003

• 20) Russell P, Robboy SJ, Anderson MC:Germ cell tumors of the ovaries. Pathology of the Female Reproductive Tract, Robboy SJ, Anderson MC and Russell P eds., 641-690, Churchill Livingstone, London, 2002

• 21) Clement PB, Young RH:Germ cell tumors of the ovary. Atlas of Gynecologic Surgical Pathology, Clement PB and Young RH eds., 338-363, W. B. Saunders Company, Philadelphia, 2000

• 22) Roth LM:Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol 25:305-320, 2006
  pubmed

• 23) Norris HJ, Zirkin HJ, Benson WL; Immature(malignant) teratoma of the ovary:a clinical and pathologic study of 58 cases. Cancer 37:2359-2372, 1976
  pubmed

• 24) O' Connor DM, Norris HJ:The influence of grade on the outcome of stage 1 ovarian immature(malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 13:283-289, 1994
  pubmed

P.138 掲載の参考文献

• 1) Silverberg SG:Histopathologic grading of ovarian carcinoma:Areview and proposal. Int J Gynecol Pathol 19:7-15, 2000.

• 2) Shimizu Y, Kamoi S, Amada S, et al:Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-Problems involved in the architectural grading system. Gynecol Oncol 70:2-12, 1998.
  pubmed

• 3) Shimizu Y, Kamoi S, Amada S, et al:Toward the development of a universal grading system for ovarian epithelial carcinoma:testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893-901, 1998.

• 4) International Federation of Gynecology and Obstetrics:Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50:1-7, 1971.

• 5) Serov SF, Scully RE, Sobin LH, eds:Histological typing of ovarian tumours. In:International Histological Classification of Tumours. No. 9, pp17-54, World Health Organization, Geneva, 1973.

• 6) Benda JA, Zaino R:GOG Pathology Manual. Gynecologic Oncology Group, NY, 1994.

• 7) Bichel P, Jakobsen A:A new histologic grding index in ovarian carcinoma. Int J Gynecol Pathol 8:147-155, 1989.
  pubmed

• 8) Elston CW, Ellis IO:Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991.

• 9) Mayr D, Diebold J:Grading of ovarian carcinomas. Int J Gynecol Pathol 19:348-353, 2000.

• 10) Malpica A, Deavers MT, Lu K, et al:Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496-504, 2004.
  pubmed

P.143 掲載の参考文献

• 1) Mair S, Lash RH, Suskin D, et al:Intraoperative surgical specimen evaluation:frozen section analysis, cytologic examination, or Both? A comparative study of 206 cases. Am J Clin Pathol 96:8-14, 1991.
  pubmed

• 2) Acs G:lntraoperative consultation in gynecologic pathology. Seminar Diagn Pathol 19:237-254, 2002.

• 3) Abrams J, Silverberg SG:The role of intraoperative cytology in the evaluation of gynecologic disease. Pathol Annual 24:167-187, 1989.

• 4) Michael CW, Lawrence WD, Bedrossian CW:Intraoperative consultation in ovarian lesions:a comparison between cytology and frozen section. Diagn Cytopathol 15:387-394, 1996.
  pubmed

• 5) Suen KC, Wood WS, Syed AA, et al:Role of imprint cytology in intraoperative diagnosis:value and limitations. J Clinic Pathol 31:328-337, 1978.

• 6) Usubutun A, Altinok G, Kucukali T:The value of intraoperative consultation(frozen section) in the diagnosis of ovarian neoplasms. Acta Obstet Gynecol Scand 77:1013-1016, 1998.
  pubmed

• 7) Gupta PK, Baloch ZB:Intraoperative and on-site cytopathology consultation:utilization, limitation, and value. Seminar Diagn Pathol 19:227-236, 2002.

• 8) Nagai Y, Tanaka N, Horiuchi F, et al:Diagnostic accuracy of intraoperative imprint cytology in ovarian epithelial tumors. Int J Gynaecol Obstet 72:159-164, 2001.
  pubmed

• 9) Pinto PB, Andrade LA, Derchain SF:Accuracy of intraoperative frozen section diagnosis of ovarian tumors. Gynecol Oncol 81:230-232, 2001.
  pubmed

• 10) Ilvan S, Ramazanoglu R, Ulker Akyildiz EU, et al:The accuracy of frozen section(intraoperative consultation) in the diagnosis of ovarian masses. Gynecol Oncol 97:395-399, 2005.

5. 分子生物学的特徴

P.150 掲載の参考文献

• 1) Sherr CJ:Gl phase progression:cycling on cue. Cell 79:551-555, 1994.

• 2) Nurse P:Ordering S phase and M phase in the cell cycle. Cell 79:547-550, 1994.

• 3) Sherr CJ, Roberts JM:Inhibitors of mammalian GI cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.

• 4) Worsley SD, Ponder BA, Davies BR:Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 64:189-195, 1997.
  pubmed

• 5) Shigemasa K, Tanimoto H, Parham GP, et al:Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 6:102-108, 1999.
  pubmed

• 6) Dhar KK, Branigan K, Parkes J, et al:Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 81:1174-1181, 1999.
  pubmed

• 7) Masciullo V, Scambia G, Marone M, et al:Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 74:390-395, 1997.
  pubmed

• 8) Barbieri F, Cagnoli M, Ragni N, et al:Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 5:1837-1842, 1999.
  pubmed

• 9) Bali A, OBrien PM, Edwards LS, et al:Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10:5168-5177, 2004.
  pubmed

• 10) Gao N, Flynn DC, Zhang Z, et al:Gl cell cycle progression and the expression of Gl cyclins are regulated by P13K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287:C281-291, 2004.

• 11) Ekholm-Reed S, Spruck CH, Sangfelt O, et al:Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res 64:795-800, 2004.
  pubmed

• 12) Farley J, Smith LM, Darcy KM, et al:Gynecologic Oncology Group. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers:a Gynecologic Oncology Group study. Cancer Res 63:1235-1241, 2003.

• 13) Marone M, Scambia G, Giannitelli C, et al:Analysis of cyclin E and CDK2 in ovarian cancer:gene amplification and RNA overexpression. Int J Cancer 75:34-39, 1998.
  pubmed

• 14) Shimizu M, Nikaido T, Toki T, et al:Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 85:669-677, 1999.
  pubmed

• 15) Tsuda H, Bandera CA, Birrer MJ, et al:Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 67:291-299, 2004.
  pubmed

• 16) Bedrosian I, Lu KH, Verschraegen C, et al:Cyclin Ederegulation alters the biologic properties of ovarian cancer cells. Oncogene 23:2648-2657, 2004.
  pubmed

• 17) Shigemasa K, Hu C, West CM, et al:p16 0verexpression:a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 4:95-102, 1997.
  pubmed

• 18) Dong Y, Walsh MD, McGuckin MA, et al:Increased expression of cyclin-dependent kinase inhibitor 2(CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74:57-63, 1997.
  pubmed

• 19) Armes JE, Lourie R, de Silva M, et al:Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 24:363-368, 2005.
  pubmed

• 20) Ryan A, Al-Jehani RM, Mulligan KT, et al:No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarlan carcinogenesls. Gynecol Oncol 68:14-17, 1998.

• 21) Wong YF, Chung TK, Cheung TH, et al:Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett 136:231-235, 1999.
  pubmed

• 22) Brown I, Milner BJ, Rooney PH, et al:Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma. Oncol Rep 8:1359-1362, 2001.

• 23) Havrilesky LJ, Alvarez AA, Whitaker RS, et al:Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol 83:491-500, 2001.
  pubmed

• 24) Kawauchi S, Liu XP, Kawasaki K, et al:Significance of beta-catenin and pRB pathway components in malignant ovarian germ cell tumours:INK4A promoter CpG island methylation is associated with cell proliferation. J Pathol 204:268-276, 2004.
  pubmed

• 25) Liu Z, Wang LE, Wang L, et al:Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 11:4968-4976, 2005.

• 26) Tsvetkov LM, Yeh KH, Lee SJ, et al:p27(Kipl) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9:661-664, 1999.

• 27) Baekelandt M, Holm R, Trope CG, et al:Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer:an immunohistochemical study. 1. Clin Cancer Res 5:2848-2853, 1999.

• 28) Palazzo JP, Monzon F, Burke M, et al:0verexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol 31:698-704, 2000.
  pubmed

• 29) Terauchi F, Okamoto A, Nagashima T, et al:Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Oncol Rep 14:363-368, 2005.
  pubmed

• 30) Werness BA, Freedman AN, Piver MS, et al:Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 75:413-418, 1999.
  pubmed

• 31) Masciullo V, Sgambato A, Pacilio C, et al:Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59:3790-3794, 1999.
  pubmed

• 32) Masciullo V, Ferrandina G, Pucci B, et al:p27Kipl expression is associated with clinical outcome in advanced epithelial ovarian cancer:multivariate analysis. Clin Cancer Res 6:4816-4822, 2000.

• 33) Newcomb EW, Sosnow M, Demopoulos RI, et al:Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154:119-125, 1999.
  pubmed

• 34) Shigemasa K, Shiroyama Y, Sawasaki T, et al:Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int J Oncol 18:953-958, 2001.
  pubmed

• 35) Korkolopoulou P, Vassilopoulos I, Konstantinidou AE, et al:The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 85:404-414, 2002.
  pubmed

• 36) Rosen DG, Yang G, Cai KQ, et al:Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11:632-637, 2005.
  pubmed

• 37) Sicinski P, Donaher JL, Geng Y, et al:Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384(6608):470-474, 1996.
  pubmed

• 38) Robker RL, Richards JS:Hormone-induced proliferation and differentiation of granulosa cells:a coordinated balance of the cell cycle regulators cyclin D2 and p27Kip1. Mol Endocrinol 12:924-940, 1998
  pubmed

P.159 掲載の参考文献

• 1) Hashimoto M, Kyo S, Masutomi K, et al:Analysis of telomeric single-strand overhang length in human endometrial cancers. FEBS Letters 579:2959-2964, 2005.
  pubmed

• 2) Allsopp RC, Vaziri H, Patterson C, et al:Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 89:10114-10118, 1992.
  pubmed

• 3) Kim NW, Piatyszek MA, Prowse KR, et al:Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994.
  pubmed

• 4) Kyo S, Takakura M, Tanaka M, et al:Telomerase activity in cervical cancer is quantitatively distinct from that in its precursor lesions. Int J Cancer 79:66-70, 1998.
  pubmed

• 5) Kyo S, Takakura M, Tanaka M, et al:Quantitative difference of telomerase activity among ovarian malignant and premalignant lesions. Clin Cancer Res 4:399-406, 1998.
  pubmed

• 6) Hiyama E, Hiyama K, Yokoyama T, et al:Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1:249-255, 1995.
  pubmed

• 7) Feng J, Funk WD, Wang SS, et al:The RNA component of human telomerase. Science 269:1236-1241, 1995.
  pubmed

• 8) Meyerson M, Counter CM, Eaton EN, et al:hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795, 1997.
  pubmed

• 9) Nakamura TM, Morin GB, Chapman KB, et al:Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959, 1997.
  pubmed

• 10) Weinrich SL, Pruzan R, Ma L, et al:Reconstitution of human telomerase with template RNA component hTERC and the catalytic protein subunit hTERT. Nature Genet 17:498-502, 1997.

• 11) Nakayama J, Tahara H, Tahara E, et al:Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature Genet 18:65-68, 1998.
  pubmed

• 12) Bodnar AG, Ouellette M, Frolkis M, et al:Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352, 1998.
  pubmed

• 13) Kyo S, Nakamura M, Kiyono T, et al:Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 163:2259-2269, 2003.
  pubmed

• 14) Maeda T, Tashiro H, Katabuchi H, et al:Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br JCancer 93:116-123, 2005.

• 15) Kusakari T, Kariya M, Mandai M, et al:C-erbB-2 or mutant Ha-ras induced malignant transformation of immortalized human ovarian surface epithelial cells in vitro. Br J Cancer 89:2293-2298, 2003.
  pubmed

• 16) Nakamura M, Masutomi K, Kyo S, et al:Efficient inhibition of hTERT expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 16:859-868, 2005.
  pubmed

• 17) Hahn WC, Stewart SA, Brooks MW, et al:Inhibition of telomerase limits the growth of human cancer cells. Nature Med 10:1129-1130, 1999.

• 18) Sun D, Thompson B, Cathers BE, et al:Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem 40:2113-2116, 1997.

• 19) Shin KH, Kang MK, Dicterow E, et al:Introduction of human telomerase reverse transcriptase to normal fibroblasts enhances DNA repair capacity. Clin Cancer Res 10:2551-2560, 2004.
  pubmed

P.167 掲載の参考文献

• 1) Kallioniemi A, et al:Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821, 1992.
  pubmed

• 2) 坂本 優, 高橋宙子:遺伝子コピー数の増減をゲノム全体について検索できる新しい分子細胞遺伝学的手法(CGH). 変異原性試験3(4):197-205, 1994.

• 3) 坂本 優, ほか:分子消化器病学に有用な技術の進歩-CGH(Comparative Genomic Hybridization) 法. 日本臨床54(4):43-53, 1996.

• 4) Ziauddin J, Sabatini DM:Microarrays of cells expressing defined cDNAs. Nature 411:107-110, 2001.
  pubmed

• 5) Schena M, Shalon D, Davis RW, et al:Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470, 1995.
  pubmed

• 6) Lockhart DJ, Dong H, Byrne MC, et al:Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680, 1996.
  pubmed

• 7) Crijns APG, et al:Molecular prognostic markers in ovarian cancer:toward patient-tailored therapy. Int J Gynecol Cancer 16:152-165, 2006.
  pubmed

• 8) Ono, et al:Identificaton by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60:5007-5011, 2000.

• 9) Okamoto A, Nikaido T, Ochiai K, et al:Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11:6030-6039, 2005.
  pubmed

• 10) Schlegel J, et al:Comparative genomic in situ hybridization of colon carcinomas with replication error. Cancer Res 55:6002-6005, 1995.
  pubmed

• 11) Iwabuchi H, Sakamoto M, et al:Genetic analysis in benign, low grade and high grade ovarian tumor. Cancer Res 55:6172-6180, 1995.
  pubmed

• 12) Shayesteh L, Pinkel D, Gray JW, et al:PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21(1):99-102, 1999.
  pubmed

• 13) Suehiro Y, Sakamoto M, Umayahara K, et al:Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59(1):50-56, 2000.
  pubmed

• 14) Umayahara K, Sakamoto M, Kato H, et al:Genetic alterations related to lymph node metastasis and peritoneal dissemination in epithelial ovarian cancers. Oncol Rep 9(5):1115-1119, 2002.
  pubmed

• 15) 坂本 優, ほか:新しい分子細胞遺伝学的方法(Comparative Genomic Hybridization) を用いた卵巣がんの抗がん剤耐性関連遺伝子マーカーの検索に関する研究. Oncology&Chemotherapy 11(2):124-132, 1995.

• 16) 坂本 優, ほか:CGHおよびLSC法を組み合わせた卵巣がんのシスプラチン耐性機構解明に関する研究. Cytometry Research 6(2):9-20, 1996.

• 17) 坂本 優, 馬屋原健司, 坂本宙子, ほか:癌遺伝子異常と薬剤感受性. 癌と化療25:1819-1831, 1998.

• 18) Sakamoto M, Ochiai K, Tanaka T, et al:Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14(4):305-315, 2001.
  pubmed

• 19) Kudoh K, Takano M, Kikuchi Y, et al:Comparative genomic hybridization for analysis of chromosomal changes in cisplatin-resistant ovarian cancer. Hum Cell 13(3):109-116, 2000.
  pubmed

• 20) Takano M, Kita T, Kikuchi Y, et al:Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncol Rep 12(6):1177-1182, 2004.
  pubmed

P.171 掲載の参考文献

• 1) King MC, Marks JH, Mandell JB:New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003.

• 2) Iba T, Kigawa J, Kanamori Y, et al:Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 95:418-423, 2004.

• 3) Cheng KW, Lahad JP, Kuo WL, et al:The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-1256, 2004.
  pubmed

• 4) Irie T, Kigawa J, Minagawa Y, et al:Alteration of a p53 gene status affects outcome of patients with recurrent ovarian cancer. Oncology 58:237-241, 2000.
  pubmed

• 5) Sato S, Kigawa J, Minagawa Y, et al:Chemosensitivity and p53-dependent apoptosis in epithelial ovarian cancer. Cancer 86:1307-1313, 1999.
  pubmed

• 6) Takahashi M, Kigawa J, Minagawa Y, et al:Sensitivity to paclitaxel is not related to P53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 36:1863-1868, 2000.

• 7) Shimada M, Kigawa J, Kanamori Y, et al:Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment. Eur J Cancer 36:1869-1875, 2000.
  pubmed

• 8) Kigawa J, Terakawa N:Cancer gene therapy:Past achievement and future challenges edited by Habibu K. Adenovirus-mediated transfer of a p53 gene in ovarian cancer, pp207-214, Plenum Publishers, New York, 2000.

P.178 掲載の参考文献

• 1) 加藤聖子, 和氣徳夫:rasとそのシグナル伝達系. 婦人科腫瘍の分子.細胞生物学新女性医学体系41, pp3-67, 中山書店, 2001.

• 2) Malumbres M, Barbacid M:Ras oncogenes:the first 30years. Nat Rev Cancer 3:7-13, 2003.

• 3) Martinez-Gac L, Alvarez B, Garcia Z, et al:Phosphoinositide 3-kinase and Forkhead, a switch for cell division. Biochem Soc Trans 32:360-361, 2004.

• 4) Cox AD, Der CJ:The dark siide of Ras:regulation of apoptosis. Oncogene 22:8999-9006, 2003.
  pubmed

• 5) Strachan T, Read AP:がんの遺伝学. ヒトの分子遺伝学第3版, pp565-589, メディカル.サイエンス.インターナショナル, 2005.

• 6) Taylor WR, Stark GR:Regulation of the G2/M transition by p53. Oncogene 20:1803-1815, 2001.
  pubmed

• 7) Wenham RM, Lancaster JM, Berchuck A:Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynecol 16:483-497, 2002.

• 8) Bell DA:Origins and molecular pathology of ovarian cancer. Mod Pathol 18:S19-S32, 2005.
  pubmed

P.184 掲載の参考文献

• 1) 植田政嗣:血管新生阻害剤による婦人科悪性腫瘍の分子標的治療. 産と婦 70:49-58, 2003.
  Medical*Online

• 2) 植田政嗣:卵巣癌における血管新生と分子標的治療. 日産婦誌 56:1283-1295, 2004.

• 3) Ueda M, Terai Y, Kanda K, et al:Tumor angiogenesis and molecular target therapy in ovarian carcinomas. Hum Cell 18:1-16, 2005.
  pubmed

• 4) Folkman J:Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995.
  pubmed

• 5) Liotta LA, Steeg PS, Stetler-Stevenson WG:Cancer metastasis and angiogenesis:an imbalance of positive and negative regulation. Cell 64:327-336, 1991.
  pubmed

• 6) Fujimoto J, Sakaguchi H, Hirose R, et al:Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83:2528-2533, 1998.
  pubmed

• 7) Yamamoto S, Konishi I, Mandai M, et al:Expression of vascular endothelial growth factor(VEGF) in epithelial ovarian neoplasms:correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227, 1997.
  pubmed

• 8) 馬場 長, 万代昌紀, 藤井信吾:卵巣癌の転移機構-腹膜播種と血管新生因子-. 日本臨床62:467-470, 2004.

• 9) 小西郁生:婦人科癌における血管新生因子. 日産婦誌52:1222-1227, 2000.

• 10) Hollingsworth HC, Kohn EC, Steinberg SM, et al:Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41, 1995.
  pubmed

• 11) Abulafia O, Triest WE, Sherer DM:Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72:220-231, 1999.
  pubmed

• 12) 加来恒壽, 平川俊夫, 小川伸二, ほか:婦人科悪性 腫瘍と組織学的にみた血管新生. 産と婦70:39-46, 2003.

• 13) Terai Y, Ueda M, Kumagai K, et al:Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum. Int J Gynecol Pathol 19:354-360, 2000.

• 14) Ueda M, Hung YC, Terai Y, et al:Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 11:3225-3232, 2005.
  pubmed

• 15) Asano M, Yukita A, Matsumoto T, et al:Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 55:5296-5301, 1995.

• 16) Wang J, Lou P, Lesniewski R, et al:Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14:13-19, 2003.
  pubmed

6. 手術療法

P.192 掲載の参考文献

• 1) Mizuno M, Kikawa F, Shibata K, et al:Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 65:29-36, 2003.

• 2) Vergote IB, Kaern J, Abeler VM, et al:Analysis of prognostic factors in stage I epithelial ovarian carcinoma:importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet gynecol 169:40-52, 1993.

• 3) 工藤隆一, 海老原敏, 吉野邦俊, ほか:日本癌治療学会リンパ節規約, 日本癌治療学会編, pp24, 金原出版, 東京, 2002.

• 4) DiRe F, Baiocchi G:Value of lymph node assessment in ovarian cancer:Status of the art at the end of the second millennium. Int J Gynecol Cancer 10:435-42, 2000.

• 5) Onda T, Yoshikawa H, Yasugi T, et al:Patients with ovarian carcinoma up staged to stage III after systematic lymphadenectomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer 83:1555-1560, 1998.

• 6) Ayhan A, Tuncer ZS, Tuncer R, et al:Is routine appendectomy beneficial in the management of ovarian cancer? Eur J Obstet Gynecol Reprod Biol 57:29-31, 1994.
  pubmed

• 7) Tay EH, Grant PT, Gebski V, et al:Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99:1008-1013, 2002.
  pubmed

• 8) Scarabelli C, Gallo A, Carbone A:Secondary cytoreductive surgery for patients with recurrent epithelial ovarlan carcinoma. Gynecol 0ncol 83:504-512, 2001.

• 9) Hoskins WJ, Rubin SC, Dulaney E, et al:Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patiens with epithelial ovarian carcinoma. Gynecol Oncol 34:365-371, 1989.

• 10) NIH consensus conference. Ovarian cancer:Screening, treatment and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273:491-497, 1995.
  pubmed

• 11) Duska LR, Chang YuC, Flynn CE, et al:Epithelial ovarian carcinoma in the reproductive age group. Cancer 85:2623-2629, 1999.

• 12) DiSaia PJ, Creasman WT:Management of early ovarian cancer in young women. In:Disaia PJ, Creasman WT, editors. Clinical Gynecologic Oncology 6thed, pp279-282, Mosby, St. Louis, 2002.

• 13) Sugiyama T, Tamura T, Kigawa J, et al:Clinical characteristics of clear cell carcinoma of the ovary:adistinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584-2589, 2000.

• 14) Zanetta G, Chiaris S, Rota S, et al:Conservative surgery for stage I ovariancarcinoma in women of childbearing age. Br J Obstet Gynecol 1O4:1030-1035, 1997.

• 15) Munnell EW:Is conservative therapy ever justified in stage I(IA) cancer of the ovary. Am J Obstet Gynecol 103:641-653, 1969.

• 16) De Poncheville L, Perrotin F, Lefrancq T, et al:Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries? Eur J Cancer 37:210-215, 2001.

P.199 掲載の参考文献

• 1) 卵巣癌の治療ガイドライン2004年版. 日本婦人科腫瘍学会/編, 東京, 金原出版, 2004.

• 2) Maker AP, Baekelandt M, Trope CG, et al:The prognostic significance of residual disease, FIGO substage, tumor histology and grade with FIGO stage III ovarian cancer. Gynecol Oncol 56:175-180, 1995.

• 3) Onda T, Yoshikawa H, Yasugi T, et al:Patients with ovarian carcinoma up-stages to stage III after systematlc lymphadennectomy have similar survival to stage III patients. Cancer 83:1555-1560, 1998.

• 4) Jacobs AJ, Deligdisch L, Deppe G, et al:Histologic correlations of virulence in ovarian adenocarcinoma. Effects of differentiation. Am J Obstet Gynecol 143:574-580, 1982.
  pubmed

• 5) Sugiyama T, Kamura T, Kigawa J, et al:Clinical characteristics of clear cell carcinoma of the ovary:a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584-2589, 2000.
  pubmed

• 6) Vergote IB, Kaern J, Abeler VM, et al:Analysis of prognostic factors in stage I epithelial ovarian cancer. Am J Obstet Gynecol 169:40-52, 1993.

• 7) Chi DS, Venkatraman ES, Masson V, et al:The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol 0ncol 77:227-231, 2000.
  pubmed

• 8) Bristow RE, Duska LR, Lambrou NC, et al:A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532-1540, 2000.

• 9) Berchuck A, Iversen ES, Lancaster JM, et al:Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190:910-925, 2004.
  pubmed

• 10) Young RC, Decker DG, Wharton JT, et al:Staging laparotomy in early ovarian cancer. JAMA 250:3072-3076, 1983.
  pubmed

• 11) Buchsbaum HJ, Brady MF, Delgado G, et al:Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 169:226-328, 1989.
  pubmed

• 12) Panici BP, Maggioni A, Hacker N, et al:Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer:a randomized clinical trial. J Natl Cancer Inst 97:560-566, 2005.

• 13) Pickel H, Lahousen M, Stettner H, et al:The spread of ovarian cancer. Baillieres Clin Obstet Gynaecol 3:3-12, 1989.
  pubmed

• 14) Rose PG, Nerenstone S, Brady MF, et al:Appendectomy in primary and secondary staging operations for ovarian malignancy. Obstet Gynecol 77:116-118, 1991.

• 15) Bristow RE, Tomacruz RS, Armstrong DK, et al:Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis. J Clin Oncol 20:1248-1259, 2002.

• 16) Eisenkop SM, Spirtos NM, Friedman RL, et al:Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer:a prospective study. Gynecol 0ncol 90:390-396, 2003.
  pubmed

• 17) Randall TC, Rubin SC:Management of intestinal obstruction in the patient with ovarian cancer. Oncology(Williston Park) 14:1159-1163, 2000.
  pubmed

• 18) Mourton SM, Temple LK, Abu-Rustum NR, et al:Morbidity of recto-sigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99:608-614, 2005.

• 19) van der Burg ME, van Lent M, Buyse M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629-634, 1995.
  pubmed

• 20) Rose PG, Nerenstone S, Brady M, et al:Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489-2497, 2004.
  pubmed

• 21) Liu PC, Benjamin I, Morgan MA, et al:Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol 0ncol 64:4-8, 1997.
  pubmed

• 22) Curtin JP, Malik R, Venkatraman ES, et al:Stage IV ovarian cancer:impact of surgical debulking. Gynecol Oncol 64:9-12, 1997.
  pubmed

• 23) Munkarah AR, Hallum AV 3rd, Morris M, et al:Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64:13-17, 1997.
  pubmed

• 24) Bristow RE, Montz FJ, Lagasse LD, et al:Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278-287, 1999.
  pubmed

P.206 掲載の参考文献

• 1) 日本産科婦人科学会編:卵巣腫瘍取扱い規約第2部, 改訂第2版, 金原出版株式会社, 東京, 1997.

• 2) 日本婦人科腫瘍学会編:卵巣がん治療ガイドライン2004年版, 第1版, 金原出版株式会社, 東京, 2004.

• 3) Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al:Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 84:1-7, 1994.
  pubmed

• 4) Dembo AJ, Davy M, Stenwig AE, et al:Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75:263-273, 1990.

• 5) Partridge EE, Gunter BC, Gelder MS, et al:The validity and significance of substages of advanced ovarian cancer. Gynecol Oncol 48:236-241, 1993.
  pubmed

• 6) Lund B, Williamson P:Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 2:281-287, 1991.
  pubmed

• 7) NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Version 1, 2005.

• 8) Trimbos JB, Vergote I, Bolis G, et al:Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma:European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95:113-125, 2003.

P.215 掲載の参考文献

• 1) 卵巣がん治療ガイドライン2004年版. 日本婦人科腫瘍学会, 金原出版.

• 2) Munnell EW, Jacox HW, Taylor HC:Treatment and prognosis in cancer of the ovary. Am J Obstet Gynecol 74:1187-1200, 1957.
  pubmed

• 3) Munnell EW:The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol 100:790-805, 1968,
  pubmed

• 4) Griffiths CT:Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101-104, 1975.
  pubmed

• 5) Hosking WJ:AMJG 170:974-980, 1994.

• 6) Makar AP, Baekelandt M, Trope CG, et al:The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175-180, 1995.
  pubmed

• 7) van der Burg ME, van Lent M, Buyse M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995.
  pubmed

• 8) 日本産婦人科学会編:卵巣腫瘍取扱い規約(第2部). 金原出版, 東京, 1992.

• 9) Piver MS, Barlow JJ, Lele SB:Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 52:100-104, 1978.

• 10) Buchsbaum HJ, Lifshitz S:Staging and surgical evaluation of ovarian cancer. Semin Oncol 11:227-237, 1984.
  pubmed

• 11) Young RC, Decker DG, Wherton JT, et al:Staging laparotomy in early ovarian cancer. JAMA 250:3072-3076, 1983.

• 12) Knapp RC, Friedman EA:Aortic lymph node metastasis in early ovarian cancer. Am J Obstet Gynecol 120:174-182, 1974.

• 13) NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, VI, 2003.

• 14) Trimbos JB, et al:For the EORTCミACTION Collaborators. Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma:European Organisation for Research and Treatment of CancerミAdjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst.

• 15) Petru E, Lahousen M, Tamussino K, et al:Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 170:656-662, 1974.

• 16) Onda T, Yoshikawa H, Yokota H, et al:Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. Cancer 78:803-808, 1996.
  pubmed

• 17) Sakuragi N, Yamada H, Oikawa M, et al:Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis(pT1MO and pT2MO). Gynecol Oncol 79:251-255, 2000.

• 18) Suzuki M, Ohwada M, Yamada T, et al:Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 79:305-308, 2000.

• 19) Hoffman MS, et al:Sites of bowel resected to achieve optimal ovarian cancer cytoreduction. Am J Obstet Gynecol 193:582-588, 2005.
  pubmed

• 20) Bonnefoi H, et al:Natural History of Stage IV Epithelial Ovarian Cancer. J Clin Oncol 17:767-775, 1995.

• 21) Todo Y, et al:Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma. Int J Clin Oncol 8:90-96, 2003.
  pubmed

• 22) Munkarah A, et al:Prognostic Significance of Residual Disease in Patients with Stage IV Epithelial Ovarian cancer. Gynecol Oncol 64:13-17, 1997.
  pubmed

• 23) Curtin JP, et al:Stage IV Ovarian Cancer:Impact of Surgical Debulking. Gynecol Oncol 64:9-12, 1997.
  pubmed

• 24) Brstiow RE, et al:Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer. Gynecol Oncol 72:278-287, 1999.

• 25) Akihira J, et al:Prognostic Factors of Stage IV Epithelial Ovarian Cancer:AMulticenter Retrospective Study. Gynecol Oncol 81:398-403, 2001.

• 26) Everett EN, et al:Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 193:568-576, 2005.
  pubmed

• 27) Eisenkop SM, Spirtas NM:Division of pedicls by stapling during cytoreductive surgery for ovarian cancer. Gynecol Oncol 97:852-857, 2005.

• 28) 日本産婦人科学会, ほか編:子宮体癌取扱い規約 第2版. 金原出版, 東京, 1996.

P.223 掲載の参考文献

• 1) FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health:FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. Int J Gynaecol Obstet 92:335-336, 2006.

• 2) Lee SJ, Schover LR, Partridge AH, et al:American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients. J Clin Oncol 24:2917-2931, 2006.

• 3) 卵巣がん治療ガイドライン. 2004年版, 日本婦人科腫瘍学会編.

• 4) Eddy CA, Asch RH, Balmaceda JP:Pelvic adhesions following microsurgical and macrosurgical wedge resection of the ovaries. Fertil Steril 33:557-561, 1980.
  pubmed

• 5) Burghardt E, Girardi F, Lahousen M, et al:Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 40:103-106, 1991.
  pubmed

• 6) Petru E, Lahousen M, Tamussino K, et al:Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 170:656-662, 1994.

• 7) Onda T, Yoshikawa H, Yokota H, et al:Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer 78:803-808, 1996.
  pubmed

• 8) Suzuki M, Ohwada M, Yamada T, et al:Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 79:305-308, 2000.

• 9) Morice P, Joulie F, Camatte S, et al:Lymph node involvement in epithelial ovarian cancer:analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197:198-205, 2003.
  pubmed

• 10) Negishi H, Takeda M, Fujimoto T, et al:Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol 0ncol 94:161-166, 2004.

• 11) Wu PC, Qu JY, Lang JH, et al:Lymph node metastasis of ovarian cancer:a preliminary survey of 74 cases of lymphadenectomy. Am J Obstet Gynecol 155:1103-1108, 1986.
  pubmed

• 12) di Re F, Baiocchi G, Fontanelli R, et al:Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer:prognostic significance of node metastases. Gynecol Oncol 62:360-365, 1996.
  pubmed

• 13) Tsumura N, Sakuragi N, Hareyama H, et al:Distribution pattern and risk factors of petvic and paraaortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer 79:526-530, 1998.
  pubmed

• 14) Parazzini F, Valsecchi G, Bolis G, et al:Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival. Gynecol 0ncol 74:7-11, 1999.
  pubmed

• 15) Eisenkop SM, Spirtos NM:The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol Oncol 82:143-149, 2001.
  pubmed

• 16) 櫻木範明, 藤堂幸治, 根岸広明, ほか:卵巣癌における傍大動脈リンパ節転移とセンチネルリンパ節, および腹腔内播種卵巣癌に対する合併切除について. 日本婦人科腫瘍学会雑誌20:194-202, 2002.

• 17) Munnell EW:Is conservative therapy ever justified in stage I(IA) cancer of the ovary? Am J Obstet Gynecol 1O3:641-650, 1969.

• 18) DiSaia PJ:Conservative management of the patient with early gynecologic cancer. CA Cancer J Clin 39:135-154, 1989.
  pubmed

• 19) Weinstein D, Polishuk WZ:The role of wedge resection of the ovary as a cause for mechanical sterility. Surg Gynecol Obstet 141:417-418, 1975.
  pubmed

• 20) Morice P, Camatte S, El Hassan J, et al:Clinical outcomes and fertility results after conservative treatment for ovarian borderline tumor. Fertil Steril 75:92-96, 2001.
  pubmed

• 21) Zanetta G, Chiari S, Rota S, et al:Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1O4:1030-1035, 1997.

• 22) Benjamin I, Morgan MA, Rubin SC:Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 72:288-291, 1999.

• 23) Morice P:Results of conservative treatment in epithelial ovarian carcinoma. Cancer 92:2412-2418, 2001.
  pubmed

• 24)Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 87:1-7, 2002.
  pubmed

• 25) Howell S, Shalet S:Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 27:927-943, 1998.
  pubmed

• 26) Meirow D, Nugent D:The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7:535-743, 2001.
  pubmed

• 27) Dnistrian AM, Schwartz MK, Fracchia AA, et al:Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 51:803-807, 1983.
  pubmed

• 28) Reichman BS, Green KB:Breast cancer in young women:effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 16:125-129, 1994.
  pubmed

• 29) Damewood MD, Grochow LB:Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 45:443-459, 1986.
  pubmed

P.233 掲載の参考文献

• 1) Hoskins WJ, Rubin SC:Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 18:213-221, 1991.
  pubmed

• 2) Baker TR, Piver MS, Hempling RE:Long term survival by cytoreductive surgery to less than 1cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 74:656-663, 1994.
  pubmed

• 3) 日本婦人科腫瘍学会:卵巣がん治療ガイドライン, pp1-80, 金原出版, 東京, 2004.

• 4) 平松祐司:開腹手術中のアクシデント:大量出血, 副損傷 産と婦 69:1207-1215, 2002.

• 5) 平松祐司, 工藤尚文:進行子宮腫瘍手術における逆行性子宮全摘術および内腸骨動脈結紮術の応用. 産婦人科手術14:145-151, 2003.

• 6) 関場香, 平松祐司:逆行性子宮全摘術. 産婦治療 62:267-273, 1991.

• 7) 平松祐司, 関場香:逆行性子宮全摘術. 子宮全摘術の実際, pp61-78, 南江堂, 東京, 1997.

• 8) 平松祐司, 関場香:広汎性子宮全摘術. 子宮全摘の実際, pp 109-138, 南江堂, 東京, 1997.

• 9) 落合和徳:卵巣癌手術-Staging laparotomy, debulking surgery, Omrntectomy, 産と婦70(増刊号):236-242, 2003.

• 10) Sonendecker EW, Beale PG:Rectosigmoid resection without colostomy during primary ytoreductive surgery for ovarian carcinoma. Int Surg 74:10-12, 1989.

• 11) 澤田俊夫, 斎藤幸夫, 洲之内広紀, ほか:腸管の手術. 桑原慶紀編, 図説産婦人科VIEW 16. 卵巣の手術. pp 130. 146, メイジカルビュー社, 東京, 1995.

• 12) 山本律, 根岸広明, 藤堂幸治, ほか:卵巣癌に対する初回手術療法-センチネルリンパ節の解析と合併切除の検討-. 産婦の実際53:47-56, 2004.

• 13) Scarabelli C, Gallo A, Franceschi S, et al:Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 88:389-397, 2000.
  pubmed

P.242 掲載の参考文献

• 1) van der Burg ME, van Lent M, Buyse M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629-634, 1995.
  pubmed

• 2) Rose PG, Nerenstone S, Brady MF, et al:Gynecologic Oncology Group:Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489-2497, 2004.
  pubmed

P.251 掲載の参考文献

• 1) Griffiths CT:Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Monogr Natl Cancer Inst 42:101-104, 1975.
  pubmed

• 2) Hoskins WJ, McGuire WP, Brady MF, et al:The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974-980, 1994.
  pubmed

• 3) Hoskins WJ, Bundy BN, Thigpen JT, et al:The influence of cytoreductive surgery on recurrence-free survival and survival in small-volume stage III epithelial ovarian cancer:A Gynecologic Oncology Group Study. Gynecol Oncol 47:159-166, 1992.

• 4) van der Burg ME, van Lent M, Buyse M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995.
  pubmed

• 5) Redman CW, Warwick J, Luesley DM, et al:Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynecol 101:142-146, 1994.

• 6) Rose PG, Nerenstone S, Brady M, et al:A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease:a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 21:201, 2002.

• 7) Gadducci A, Iacconi P, Fanucchi A, et al:Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Anticancer Res 20:1959-1964, 2000.
  pubmed

• 8) Munkarah AR, Coleman RL:Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95:273-280, 2004.
  pubmed

• 9) Diaz-Montes TP, Bristow RE:Secondary cytoreduction for patients with ovarian cancer, Current Oncology Reports 7:451-458, 2005.
  pubmed

• 10) Harter P:Preoperative selection criteria for operability in recurrent ovarian cancer:AGO-OVAR. Proc Am Soc Clin Oncol 456:5004, 2005.

• 11) Chi DS, McCaughty K, Diaz JP, et al:Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinOma.
  pubmed

P.258 掲載の参考文献

• 1) van der Burg ME, van Lent M, Buyse M et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629-634, 1995.
  pubmed

• 2) Rose PG, Nerenstone S, Brady MF, et al:Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489-2497, 2004.
  pubmed

• 3) Armstrong DK, Bundy B, Wenzel L, et al:Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006.
  pubmed

• 4) Sakuragi N, Nakajima A, Nomura E, et al:Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol Oncol 79:420-423, 2000.
  pubmed

• 5) Adachi S, Noda T, Ito K, et al:Complications associated with CDDP intraperitoneal chemotherapy. Asia Oceania J Obstet Gynaecol 20:7-12, 1994.
  pubmed

• 6) Piccart MJ, Speyer JL, Markman M, et al:Intraperitoneal chemotherapy:technical experience at five institutions. Semin Oncol 12(Suppl 4):90-96, 1985.

• 7) Rubin SC, Hoskins WJ, Markman M, et al:Long-term access to the peritoneal cavity in ovarian cancer patients. Gynecol Oncol 33:46-48, 1989.

P.261 掲載の参考文献

• 1) 日本産科婦人科学会編:卵巣腫瘍取扱い規約第2部改定第2版, 金原出版株式会社, 東京, 1997.

• 2) 塩田 充ほか:産婦人科手術16:114-118, 2005.

• 3) NIH Consensus Statements:Ovarian cancer screening, treatment, and follow-up. JAMA 273:491-497, 1995.

• 4) Nezhat F, Nezhat C, Welander, et al:Four ovarian cancers diagnosed during laparoscopic management of 1011 woman with adnexal masses. Am J Obstet Gynecol 167(3):790-796, 1992.
  pubmed

• 5) Mettler L, Jacobs V, Brandenburg K, et al:Laparoscopic Management of 641 Adnexal Tumors in Kiel, Germany. J Am Assoc Gynecol Laparosc 8(1):74-82, 2001.

• 6) Vergote I, De Brabanter J, Fyles A, et al:Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. LANCET 357(9251):176-182, 2001.

• 7) Canis M, Rabischong B, Houlle C, et al:Laparoscopic management of adnexal masses:a gold standerd? Curr Opin Obstet Gynecol 14(4):423-428, 2002.

• 8) Ahmed FY, et al:Natural History and Prognosis of Untreated Stage I Epithelial Ovarian Carcinoma. J Clin Onkol 14:2968-2975, 1996.

• 9) Dembo AJ, Davy M, Stenwig AE, et al:Prognostic factors in patients with stage I epithelial ovarian cancer. Obst.Gynecol 75(2):263-273, 1990.

• 10) Childers JM, Aqua KA, Surwit EA, et al:Abdominal-wall tumor implantation after laparoscopy for malignant conditions. Obstet Gynecol 84(5):765-769, 1994.
  pubmed

• 11) Leminen A, Lehtovirta P, et al:Spread of ovarian cancer after laparoscopic surgery:report of eight cases. Gynecol Oncol 75(3):387-390, 1999.
  pubmed

• 12) Smidt VJ, Singn DM, Hurteau, et al:Effect of carbon dioxide on human ovarian carcinoma cell growth. Am J Obstet Gynecol 185(6):1314-1317, 2001.

• 13) Nicoletto MO, Tumolo S, Talamini R, et al:Surgical second look in ovarian cancer:arandomized study in patients with laparoscopic complete remission-a Northeastem Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol 15(3):994-999, 1997.

P.267 掲載の参考文献

• 1) 赤枝朋嘉, 井坂恵一:研修医のための必修知識(婦人科疾患の診断.治療.管理8. 手術). 日本産科婦人科学会誌56:N162-N166, 2004,

• 2) 大杉治司:消化器系術後合併症の対策と治療. 外科治療90:746-751, 2004.

• 3) 安達洋祐, 竹中元康, 十肥修司, ほか:術後の疼痛管理. 外科67:1255-1259, 2005.

• 4) 工藤隆一, 竹原正輝, 鈴木孝浩:術後感染予防. 52:359-364, 2000.

• 5) 平井正文:深部静脈血栓症と急性肺塞栓症. 臨床外科60:293-297, 2005.

7. 薬物療法

P.273 掲載の参考文献

• 1) 黒石哲生, 広瀬かおる, 富永祐民, ほか:がん統計白書-罹患/死亡/予後-2004, 1, 大島明, 篠原出版, 東京, 2004.

• 2) 吉田富子:癌の化学療法について. 化学療法とホルモン療法2:1-9, 1949.

• 3) Rosenberg B, Van Camp L, Krigas T:Inhibition of cell division in Escherichea colli by electrolysis products from a platinum electrode. Nature 205:698-699, 1965.

• 4) Rosenberg B, Van Camp L:The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res 30:1799-1802, 1970.
  pubmed

• 5) Advanced ovarian cancer trialists group:Chemotherapy in advanced ovarian cancer:a randomized clinical trials. Br Med J 303:884-893, 1991.

• 6) Omura G, Blessing JA, Ehrlich CE, et al:A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57:1725-1730, 1986.
  pubmed

• 7) Conte PF, Bruzzone M, Chiara S, et al:A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 4:965-971, 1986.
  pubmed

• 8) McGuire WP, Hoskins WJ, Brady MF, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stade IV ovarian cancer. N Eng J Med 334:1-6, 1996.

• 9) Carbert AH, Newell DR, Gumbrell JA, et al:prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989.

• 10) 卵巣がん治療ガイドライン2004年版1, 日本婦人科腫瘍学会, 金原出版, 東京, 2004.

P.279 掲載の参考文献

• 1) 卵巣がん治療ガイドライン2004年版(日本婦人科腫瘍学会編), 金原出版, 東京, 2004.

• 2) McGuire WP, Hoskins WJ, Brady MF, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.
  pubmed

• 3) Piccart MJ, Bertelsen K, James K, et al:Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:three-year results. J Natl Cancer Inst 92:699-708, 2000.
  pubmed

• 4) Ozols RF, Bundy BN, Greer BE, et al:Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer:a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003.

• 5) Du Bois A, Luck HJ, Meier W, et al:A randomized clinical trial of cisplatin/paclitaxel versus catboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer lnst 95:1320-1329, 2003.

• 6) Vasey PA:Survival and long-termtoxicity results of the SCOTROC study:docetaxel-carboplatin(DC) vs. paclitaxel-carboplatin(PC) in epithelial ovarian cancer(EOC). Proc Am Soc Clin Oncol 21:202a, 2002.

• 7) Du Bois A, Combe M, Rochon J, et al:Epirubicin/paclitaxel/carboplatin(TEC) vs paclitaxel/carboplatin(TC) in first-line treatment of ovarian cancer(OC) FIGO stages IIB-IV. An AGOGINECO Intergroup phase III trial. Proc Am Soc Clin Oncol 21:449(abstr 5007), 2004.

• 8) Markman M, Liu PY, Wilczynski S, et al:Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy:A Southwest Oncology Group and Gynecologic Oncology Group triaL J Clin Oncol 21:2460-2465, 2003.

• 9) Armstrong DK, Bundy BN, Baergen R, et al:Randomized phase III study of intravenous(IV) paclitaxel and cisplatin versus IV pac[itaxel, intraperitoneal(IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer(OC):aGynecologic Oncology Group trial(GOGI72). Proc Am Soc Clin Oncol 21:201a(abstr 803), 2002.

• 10) Vergote IB, Trimbos BJ, Guthrie D, et al:Results of arandomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery. Proc Am Soc Clin Oncol 20:201a, 2001.

• 11) Van der Burg MEL, Van Lent M, et al:The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332:629-634, 1995.

• 12) Rose PG, Nerenstone S, Brady M, et al:A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease:a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 21:201a, 2002.

P.287 掲載の参考文献

• 1) Berek JS, Hacker NF:Practical Gynecologic Oncology, 3rd ed. Lippincott Williams & Wilkins, 2000.

• 2) Hoskins WJ, Perez CA, Young RC:Principles and Practice of Gynecologic Oncology, 3rd ed. Lippincott Williams & Wilkins, 2000.

• 3) DiSaia PJ, Creasman WT:Clinical Gynecologic Oncology, 6th ed. Mosby, 2002.

• 4) Gershenson DM, McGuire WP, Gore M, et al:Gynecologic Cancer:Controversies in Management. Churchill Livingstone, 2004.

• 5) 池田俊一, 西條長宏:卵巣癌の化学療法Evidence Based Medicine[EBM]を目指して. 株式会社メディカルコミュニケーションズ.

• 6) 卵巣がん治療ガイドライン2004年版, 日本婦人科腫瘍学会編集, 2004.

P.293 掲載の参考文献

• 1) Covens AL:A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78:269-274, 2000.
  pubmed

• 2) 恩田貴志:特集Neoadjuvant chemotherapy卵巣癌. 癌治療と宿主14:65-71, 2004.

• 3) Kuhn W, Rutke S, Spathe K, et al:Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92:2585-2591, 2001.
  pubmed

• 4) Jacob JH, Gershenson DM, Morris M, et al:Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 42:146-150, 1991.
  pubmed

• 5) Onnis A, Marchetti M, Padovan P, et al:Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 17:393-396, 1996.
  pubmed

• 6) Kayikgoglu F, Kose MF, Boran N, et al:Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11:466-470, 2001.
  pubmed

• 7) Schwartz PE, Rutherford TJ, Chambers JT, et al:Neoadjuvant chemotherapy for advanced ovarian cancer:long-term survival. Gynecol Oncol 72:93-99, 1999.
  pubmed

• 8) Vergote I, De Wever I, Tlalma W, et al:Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma:aretrospective analysis of 285 patients. Gynecol 0ncol 71:431-436, 1998.

• 9) Vergote I, de Wever I, Tjalma W, et al:Interval debulking surgery:an alternative for primary surgical debulking? Semin Surg Oncol 19:49-53, 2000.

P.299 掲載の参考文献

• 1) Miyagi Y, Fujiwara K, Kigawa J, et al:Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmaco-kinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-A Sankai Gynecology Study Group(SGSG) study. Gynecol Oncol 99:591-596, 2005.

• 2) Markman M, Brady MF, Spirtos NM, et al:Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum:a Gynecologic Oncology Group Study. J Clin Oncol 16:2620-2624, 1998,

• 3) Rothenberg ML, Liu PY, Braly PS, et al:Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer:results from an intergroup Phase II trial JClin Oncol 21:1313-1319, 2003.

• 4) Armstrong DK, Bundy B, Wenzel L, et al:Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006.
  pubmed

• 5) Alberts DS, Liu PY, Hannigan EV, et al:Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl JMed335:1950-1955, 1996.
  pubmed

• 6) Markman M, Bundy BN, Alberts DS, et al:Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravcnous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma:an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastem Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001.

• 7) Fujiwara K, Sakuragi N, Yoshida N, et al:First-Line Intraperitoneal Carboplatin-Based Chemotherapy for 165 Patients With Epithelial Ovarian Carcinoma:Results of Long-term Follow-up. Gynecol Oncol 90:637-643, 2003.
  pubmed

• 8) Walker JL, Armstrong DK, Huang HQ, et al:Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer:A Gynecologic Oncology Group Study. Gynecol Oncol 100:27-32, 2006.

• 9) Markman M, Walker JL:Intraperitoneal chemotherapy of ovarian cancer:a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988-994, 2006.
  pubmed

P.304 掲載の参考文献

• 1) Markman M:Single-agent carboplatin is the treatment of choice in recurrent, potentially platinum-sensitive epithelial ovarian cancer. ASCO Educational Book. 38th Annual Meeting:521-523, 2002.

• 2) ten Bokkel Huinink W, Gore M, Carmichael J, et al:Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.
  pubmed

• 3) Gordon AN, Fleagle JT, Guthrie D, et al:Recurrent epithelial ovarian carcinoma:a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001.

• 4) Cantu MG, Buda A, Parma G, et al:Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patient swith recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232-1237, 2002.

• 5) Bolis G, Scarfone G, Giardina G, et al:Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cispiatin or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81:3-9, 2001.

• 6) Parmer MK, Ledermann JA, Colombo N, et al:Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003.

• 7) Bolis G, Parazzini F, Scarfone G, et al:Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and-resistant ovarian cancer. Gynecol Oncol 72:60-64, 1999.
  pubmed

• 8) De Wit R, van der Burg ME, van den Gaast A, et al:Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 5(7):656-657, 1994.
  pubmed

• 9) Rose PG, Blessing JA, Mayer AR, et al:Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum sensitive ovarian carcinoma:a Gynecologic Oncology Group study. J Clin Oncol 16(2):405-410, 1998.

• 10) Seymour MT, Mansi JL, Gallagher CJ, et al:Protracted oral etoposide in epithelial ovarian cancer:a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 69(1):191-195, 1994.
  pubmed

• 11) Lund B:Phase II study of gemcitabine in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994.
  pubmed

P.308 掲載の参考文献

• 1) Mitchell PL, Al-Nasiri, Gore M, et al:Treatment of Nondysgerminomatous Ovarian Germ Cell Tumors. An Analysis of 69cases. Cancer 85:2232-2244, 1999.
  pubmed

• 2) Lai CH, Chang TC, Wang PN, et al:Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 96:784-791, 2005.
  pubmed

• 3) Billmire D, Vinocur F, Olson T, et al:Outcome and Staging evaluation in Malignant Germ Cell Tumors of the Ovary in Children and Adolescents:An Intergroup Study. J of Pediatric Surgery 39:424-429, 2004.

• 4) Messing MJ, Gershenson DM, Morris M, et al:Primary treatment failure in patients with malignant ovarian germ cell neoplasms. Int J Gynecol Cancer 2:295-300, 1992.
  pubmed

• 5) Williams SD, Blessing JA, Homesley HD, et al:Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors:a trial of the Gynecologic Oncology Group. Ann Intern Med 11:22-27, 1989.

• 6) Munkarah A, Gershenson DM, Morris M, et al:Salvage Surgery for Chemorefactory Ovarian Germ Cell Tumor. Gynecol Oncol 55:217-223, 1994.

• 7) Loehrer P, Gronin R, Einhorn H, et al:Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998.

• 8) Nichols CR, Tricot G, Williams SD, et al:Dose-intensive chemotherapy in refractory germ cell cancer; a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989.
  pubmed

• 9) Motzler RJ, Gulati SC, Herr H, et al:High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550-556, 1992.

• 10) Mandanas RA, Saez RA Selby GB, et al:Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 21:569-576, 1998.

• 11) Beyer J, Stenning S, Siegert W, et al:High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors:a matched-pair analysis. Ann Oncol 13:599-605, 2002.
  pubmed

• 12) Motzer R, Sheinfeld J:Poor-Risk testicular cancer and high-dose chemotherapy. J Clin Oncol 22:5073-4074, 2003.

• 13) Motzer JM, Sheinfeld J, Bosl GJ, et al:Paclitaxel, ifosfamide, and cisplatin second-line Therapy for patients with relapsed testicular germ cell cancer:J, Clin Oncol 18:2413-2418, 2000.

• 14) Hinton S, Catalano P, Wilding G, et al:Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors(E9897):A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20:1859-1863, 2002.

• 15) Kollmannsbeger C, Beyer J, Bokemeyer, et al:Combination chemotherapy with Gemcitabine plus Oxaliplatin in patients with intensively pretreated or refractory germ cell cancer; A study of the German Testicular Cancer study group. J Clin Oncol 22:108-114, 2004.

• 16) McNeish IA, Kanfer EJ, Seckl MJ, et al:Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumors Br J Cancer 90:1169-1175, 2004.
  pubmed

• 17) Rezek Y, Sheinfeld J, Chi DS:Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma:a case report and review of the literature. Gynecol Oncol 96:883-887, 2005.

• 18) Beyer J, Kingreen D, Siegert W, et al:Long term survival of patients with recurrent of refractory germ cell tumors after high dose chemotherapy. Cancer 79:161-168, 1997.
  pubmed

P.314 掲載の参考文献

• 1) Hatae M, Onishi Y, Noda K, et al:Randomized trial on adjuvant iv chemotherapy CDDP+CPA versus PO chemotherapy CPA for stage Ia ovarian cancer by the Japanese Gynecologic Oncology and Chemotherapy Study Group(Meeting abstract). ASCO Annual Meeting Abstract No:1412, 1998.

• 2) Alberts DS, Liu PY, Hannigan EV, et al:Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 335:1950-1955, 1996.
  pubmed

P.321 掲載の参考文献

• 1) 藤原恵一, 河野一郎, 波多江正紀, ほか:婦人科がん多施設共同研究の現状と将来像欧米の臨床研究グループに学ぶ. Gynecologic Oncology Group(GOG). 産科と婦人科72(9):1105-1111, 2005.

• 2) 寒河江悟:婦人科がん多施設共同研究の現状と将来像. 欧米の臨床研究グループに学ぶ. European Organization for Research and Treatment of Cancer(GCIG). 産科と婦人科72(9):1112-1119, 2005.

• 3) Organization Current Research and Strategies 2005-2006, European Organisation for Research and Treatment of Cancer. 2005.

P.328 掲載の参考文献

• 1) Olayioye MA, Graus-Porta D, Beerli RR, et al:ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18:5042-5051, 1998.
  pubmed

• 2) Meden H, Marx D, Roegglen T, et al:Overexpression of the oncogene c-erbB-2(HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 17(1):61-65, 1998.
  pubmed

• 3) Baselga J, Averbunch SD:ZD1839('lressa') as an anticancer agent. Drugs 60 Suppl 1:33-40, 2000.

• 4) Giaccone G, Herbst RS, et al:Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase III trial--INTACT 1 J Clin Oncol 22(5):777-784, 2004.
  pubmed

• 5) Herbst RS, Giaccone G, et al:Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase III trial--INTACT 2. J Clin Oncol 22(5):785-794, 2004.
  pubmed

• 6) hatcher N, et al:Results of a Phase III placebo-controlled study(ISEL) of gefitinib(IRESSA) plus best supportive care(BSC) in patients with advanced non-small-cell lung cancer(NSCLC) who had received 1 or 2 prior chemotherapy regimens[abstract#LB-6]. ISEL Investigators, AACR 96th Annual Meeting, 2005.

• 7) Lynch TJ, Bell D, et al:Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med 350:2129-2139, 2004.
  pubmed

• 8) Paez JG, Janne PA, Lee JC, et al:EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science 10.1126/science. 1099314(2004).

• 9) RJ Schilder, E Kohn, MW Sill, et al:Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer:Gynecology Oncology Group 170C Proc ASCO 22:451, 2003(abstr1814).

• 10) Roman Perez-Soler, Abraham Chachoua, Mark Huberman, et al:A Phase II Trial of the Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients(pts) with Advanced, EGFR-Expressing, Non-Small Cell Lung Cancer(NSCLC). Proc ASCO 20:abstr 1235, 2001.

• 11) FA Shepherd, et al:A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer(NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group(NCIC CTG) trial. ASCO Annual Meeting Abstract No:7022, 2004.

• 12) Slamon DJ, Leyland-Jones B, Shak S, et al:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792, 2001.

• 13) Michael A Bookman, Kathleen M Darcy, et al:Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2:A Phase II Trial of the Gynecologic Oncology Group. Journal of Clinical Oncology Vol 21, Issue 2(January):283-290, 2003.

• 14) Cho HS, Mason K, Ramyar KX, et al:Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421(6924):756-760, 2003.
  pubmed

• 15) Savage DG, Antman KH:Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346(9):683-693, 2002.
  pubmed

• 16) Rak JW, BD St Croix, et al:Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 6(1):3-18, 1995.

• 17) Dvorak HF:Vascular permeability factor/vascular endothelial growth factor:a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368-4380, 2002.

• 18) Carmeliet P:Mechanisms of angiogenesis and arteriogenesis. Nat Med 6(4):389-395, 2000.
  pubmed

• 19) Anon:Bevacizumab:anti-VEGF monoclonal antibody, Avastin, Rhumab-VEGF. Drugs R&D 3(1):28-30, 2002.

• 20) H Hurwitz, et al:Bevacizumab(a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer(CRC):Results of a phase III trial of bevacizumab in combination with bolus IFL(irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC PROC ASCO(abstr) 3646, 2003.

• 21) Shepherd FA, Giaccone G, Seymour L, et al:Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer:a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20(22):4434-4439, 2002.

• 22) Michael Smylie, Richard Mercier, David Aboulafia, et al:Phase III Study of the Matrix Metalloprotease(MMP) Inhibitor Prinomastat in Patients Having Advanced Non-Small Cell Lung Cancer(NSCLC). Proc ASCO 20:abstr 1226, 2001.

• 23) Carlson BA, Dubay MM, Sausville EA, et al:Flavopiridol induces Gl arrest with inhibition of cyclin-dependent kinase(CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56(13):2973-2978, 1996.

• 24) Yamada Y, et al:Phase I pharmacokinetic and pharma-cogenomic study of E7070 administered once every 21 days. Cancer Sci 96(10):721-728, 2005.

P.336 掲載の参考文献

• 1) Bookman MA, et al:Topotecan for the treatment of advanced epithelial ovarian cancer:an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatirl and paclitaxel. J Clin Oncol 16:3345-3352, 1998.
  pubmed

• 2) ten Bokkel Huinink W, et al:Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.
  pubmed

• 3) Gordon AN, et al:Recurrent epithelial ovarian carcinoma:a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001.

• 4) Hoskins PJ, Swenerton KD:Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994.
  pubmed

• 5) Alici S, Saip P, Eralp Y, et al:Oral etoposide(VP16) in platinum-resistant epithelial ovarian cancer(EOC). Am J Clin Oncol 26:358-362, 2003.
  pubmed

• 6) Rose PG, Blessing JA, Mayer AR, et al:Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma:a Gynecologic Oncology Group study. J Clin Oncol 16:405-410, 1998.

• 7) D, Agostino G, Amant F, Berteloot P, et al:Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88:266-269, 2003.
  pubmed

• 8) Lund B, Hansen OP, Theilade K, et al:Phase II study of gemcitabine(2', 2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86, 1530-1533, 1994.
  pubmed

• 9) Markman M, et al:Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90:593-596, 2003.
  pubmed

• 10) Sorensen P, et al:Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 81:58-62, 2001.
  pubmed

• 11) Bajetta E, et al:Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer:activity in platinum-resistant disease. J Clin Oncol 14:2546-2551, 1996.

• 12) Sessa C, et al:Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-1874, 2005.

• 13) Valoti G, et al:Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977-1983, 1998.
  pubmed

• 14) Richardson PG, et al:Bortezomib or high-dose dexa-methasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005.

• 15) Aghajanian C, et al:Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23:5943-5949, 2005.

• 16) Sabbatini P, et al:Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22:4523-4531, 2004.

• 17) Rose PG:Pegylated liposomal doxorubicin:optimizing the dosing schedule in ovarian cancer. Oncologist 1O:205-214, 2005.

• 18) Kavanagh JJ, et al:Multi-institutional phase 2 study of TLK286(TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 15:593-600, 2005.
  pubmed

• 19) Boehmer C, Jaeger W:Capecitabine in treatment of platinum-resistant recurrent ovarian cancer. Anticancer Res 22:439-443, 2002.
  pubmed

• 20) Vasey PA, McMahon L, Paul J, et al:A phase II trial of capecitabine(Xeloda) in recurrent ovarian cancer. Br J Cancer 89:1843--1848, 2003.

• 21) Rischin D, et al:A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol 93:417-421, 2004.
  pubmed

P.342 掲載の参考文献

• 1) 礒西成治:卵巣がん化学療法における薬剤耐性と細胞内シグナル伝達機構. 日産婦誌51:539-540, 1999.

• 2) Spentzos D, Levine DA, Kolia S, et al:Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer. J Clin Oncol 23:7911-7918, 2005.
  pubmed

• 3) Auersperg N, Wong AS, Choi KC, et al:Ovarian surface epithelium. biology, endocrinology, and pathology. Endocr Rev 22:255-288, 2001.
  pubmed

• 4) Hilger RA, Scheulen ME, Strumberg D:The Ras-Raf-MEK-ERK pathway in the streatment of cancer. Onkologie 25:511-518, 2002.

• 5) Adjei AA, Croghan GA, Erlichman C, et al:Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 9:2520-2526, 2003.
  pubmed

• 6) Dy GK, Bruzek LM, Croghan GA, et al:A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res 1; 11:1877-1883, 2005.
  pubmed

• 7) Asselin E, Mills GB, Tsang BK:Xiap regulates Akt activity and caspase-3-dependent cleavage during cisplatin induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61:1862-1868, 2001.
  pubmed

• 8) Lee S, Choi EJ, Jin C, et al:Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97(1):26-34, 2005.

• 9) Page C, Lin HJ, Jin Y, et al:Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20:407-416, 2000.
  pubmed

• 10) Weichert W, Gekeler V, Denkert C, et al:Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol 23:633-639, 2003.
  pubmed

• 11) Isonishi S, Ohkawa K, Tanaka T, et al:Depletion of protein kinase C(PKC) by 12-O-tetradecanoylphorbol-13-acetate(TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer 82:34-38, 2000.
  pubmed

• 12) Yuen AR, Halsey J, Fisher GA, et al:Phase I study of an antisense oligonucleotide to protein kinase C-alpha(ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5:3357-3363, 1999.
  pubmed

• 13) Mor G, Straszewski S, Kamsteeg M:Role of the Fas/Fas ligand system in female reproductive organs:survival and apoptosis. Biochem Pharmacol 64:1305-1315, 2002.
  pubmed

• 14) Isonishi S, Saitou M, Ochiai K, et al:Mitochondria in platinum resistant cells. Human Cell l4:203-210, 2001.

• 15) Isonishi S, Saitou M, Yasuda M, et al:Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells. Gynecol Oncol 90:413-420, 2003.
  pubmed

• 16) Aghajanian C, Dizon DS, Sabbatini P, et al:Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23:5943-5949, 2005.
  pubmed

• 17) Kavanagh JJ, Gershenson DM, Choi H, et al:Multi-institutional phase 2 study of TLK286(TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 15:593-600, 2005.
  pubmed

• 18) Kavallaris M Kuo D Y-S, Catherine A, et al:Taxol-resistant Epithelial Ovarian Tumors Are Associated with Altered Expression of Specific B-Tubulin Isotypes. J Clin Invest lOO:1282-1293, 1997.

• 19) Mozzetti S, Ferlini C, Concolino P, et al:Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res l; 298-305, 2005.

• 20) Marcus AI, Peters U, Thomas SL, et al:Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and-sensitive cancer cells. J Biol Chem 25 ; 11569-11577, 2005.

• 21) Rose PG:Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 15 Suppl 1:18-22, Review, 2005.

• 22) Bookman MA:Gemcitabine monotherapy in recurrent ovarian cancer:from the bench to the clinic. Int J Gynecol Cancer 15 Suppl 1; 12-17, Review, 2005.

• 23) Armstrong DK, Bundy B, Wenzel L, et al:Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med 354:34-43, 2006.
  pubmed

P.354 掲載の参考文献

• 1) Kondo T:Prediction of response of tumor and host to cancer chemotherapy. Natl Cancer Inst Monograph 34:251-256, 1971.

• 2) Ichihashi H, Kondo T, Sakakibara S, et al:Application of rapid in vitro test for the evaluation of sensitivity of cancer cells to anticancer drugs. Oncology 41:88-95, 1984.

• 3) 野宗義博, 西山雅彦, 山口昌宏ほか:ヌードマウスを用いた制癌剤感受性決定とその臨床評価. 癌と化学療法13:1221-1226, 1986.

• 4) Ovejera AA, Houchens DP, Baker AD:Chemotherapy of human tumor xenografts in genetically athymic nude mice. Ann Clin Lab Sci 8:50-56, 1978.

• 5) Ichihashi H, Sako T, Kondo T:In vitro soft agar assay by use of multiplate for screening of tumor sensitivity to anticancer drugs. Jpn Surg 13:549-553, 1983.

• 6) Carmichael J, DeGraff WG, Gazdar AF:Evaluation of a tetrazolium-based semiautomated colorimetric assay:Assessment of chemosensitivity testing. Cancer Res 47:936-942, 1987.
  pubmed

• 7) Michaelopoulos G, Pitot H:Primary culture of parenchymal liver cells on collagen membranes. Exp Cell Res 94:70-78, 1975.

• 8) 小林昶運, 谷坂圭造, 近藤直人ほか:新しいin vitro 抗癌剤感受性試験Collagen Gel Droplet Embedded Culture Drug Sensitivity Test(CD-DST) 法の確立とそ の臨床有用性の検討.
  Medical*Online

• 9) 斎藤和子, 佐々田裕子, 夏野徹也ほか:制癌剤感受性テスト, SDIの改良法7:1952-1958, 1980.

• 10) Iwahashi M:Chemosensitivity test of fresh human cancer in vitro highly purified tumor cells using MTT assay. 24th Annual Meeting of Japan Human Cell Society, pp24, 2006.

• 11) Koetsuka M, Kondo N, Kobayashi H, et al:Drug sensitivity test for primary culture of human cancer cells using collagen embedded culture and image analysis. Int J Oncol 2:953-959, 1993.

• 12) Tanigawa N, Kitaoka A, Yamakawa M, et al:In vitro chemo sensitivity testing of human tumors by collagen droplet culture and image analysis. Anticancer Res 16:1925-1930, 1996.

• 13) Amano Y, Okumura C, Ishikawa H, et al:Measuring Respiration of Cultured Cell with Oxgen Electrode as a Metabolic Indicator for Drug Screening. HUMAN CELL 12:340, 1999.

• 14) Uesu K, Ishikawa H:酸素電極を用いた抗癌剤の感受性試験の解析. 日本大学松戸歯学部一般教育紀要 28:104-117, 2002.

• 15) Uesu K, Ishikawa H:酸素電極を用いての培養中の酸素濃度の識別について. 日本大学松戸歯学部一般教育紀要8:9-19, 2005.

• 16) Uesu K, Ishikawa H:Analysis of an ln Vitro Susceptibility Test of Anticancer Drugs Using New Types of Oxgen Electrode. 日本大学松戸歯学部一般教育紀要7:7-21, 2005.

• 17) Ishiwata I, Ishiwata C, Tsuiki, A, Kiguchi K, Hashimoto, Hand Ishikawa H; Estabkishment and characterization of a human gestational choriocarcinoma cell line(HOCC). Human Cell, 17:33-41, 2004.

P.362 掲載の参考文献

• 1) Robinson W, Adams W, Marrogi A, et al:Vaccine therapy for ovarian cancer using herpes simplex virus-thymidine kinase(HSV-TK) sui.cide gene transfer technique:aphase I study. Gene Ther Mol Biol 2:31-40, 1998.

• 2) Deisseroth AB, Kavanagh J, Champlin R:Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer:pilot trial. Hum Gene Ther 5:1507-1522, 1994.
  pubmed

• 3) Alvarez RD, Barnes MN, Gomez-Navarro J, et al:A cancer gene therapy approach utilizing an anti-erbB-2 single chain antibody-encoding adenovirus(AD21):a phase I trial. Clin Cancer Res 6:3081-3087, 2000.

• 4) Alvarez RD, Gomez-Navarro J, Wang M, et al:Adenoviral mediated suicide gene therapy for ovarian cancer. Mol Ther 2:524-530, 2000.
  pubmed

• 5) Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer:2. 5-Year follow-up. Gynecol Oncol 83:549-554, 2001.
  pubmed

• 6) Hortobagyi GN, Ueno NT, Xia W, et al:Cationic liposome-mediated EIA gene transfer to human breast and ovarian cancer cells and its biologic effects:aphse I clinical trial. J Clin Oncol l9:3422-3433, 2001.

• 7) Madhusudan S, Tamir A, Bate N, et al:A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of EIA-lipid complex in patients with recurrent epithelial ovarian cancer overexperssing HER2/neu oncogene. Clinical Cancer Research 10:2986-2996, 2004.

• 8) WolfJK, Jenkins AD:Gene therapy for ovarian cancer(Review). Int J Oncol 21:461-468, 2002.
  pubmed

• 9) Wolf JK, Bodurka DC, Gano JB, et al:A phase I study of Adp53(INGN201:ADVEXIN) for patients with platinum-and paclitaxel-resistent epithelial ovarian cancer. Gynecologic Onclogy 94:442-448, 2004.

• 10) Buller RE, Runnebaum IB, Karlan BY, et al:A phase I/II trial of rAd/p53(SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Therapy 9:553-566, 2002.
  pubmed

• 11) Tait DL, Obermiller PS, Fraziier SR, et al:Aphase Itrial of retroviral BRCAI vs gene therapy in ovarian cancer. Clin Cancer Res 3:1959-1968, 199712) Tait DL, Obermiller PS, Hatmaker RA, et al:Ovarian cancer BRCAI gene. Phase I and phase II trial differences in immune response and vector stability. Clin. Cancer Res 5:1708-1714, 1999.

• 13) Vasey PA, Shulman LN, Campas S, et al:Phase I trial of intraperitoneal injection of the E IB-55-kd-gene-deleted adenovirus ONYX-Ol5(dl l520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20:1562-1569, 2002.

• 14) Kirn D:Clinical research results with dll520(ONYX-Ol5), a replication-selective adenovirus for the treatment of cancer:whtat have we learned? Gene Therapy 8:89-98, 2001.

• 15) DeWeese TL, van der Poel H, Li S, et al:A phse I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research 61:7464-7472, 2001.

• 16) Nakao A, Kimata H, Imai T, et al:Intratumoral injection of herpes simplex HF10 in recurrent breast cancer. Annals of Oncol l 5:988-989, 2004.

P.371 掲載の参考文献

• 1) Coussens L, Yang-Feng TL, Liao YC, et al:Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985.
  pubmed

• 2) Slamon DJ, Godolphin W, Jones LA, et al:Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
  pubmed

• 3) Lin JT, Wu MS, Shun CT, et al:Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 0ncoprotein. Cancer Res 55:1428-1430, 1995.
  pubmed

• 4) Osaki T, Mitsudomi T, Oyama T, et al:Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 108:157-162, 1995.
  pubmed

• 5) Nagata Y, Furugen R, Hiasa A, et al:Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol l59:1336-1343, 1997.

• 6) 奥川利治, 生田安司, 永田康浩, ほか:HER2ペプチドを用いた免疫療法の可能性. 医学のあゆみ 190:125-128, 1999.
  Medical*Online

• 7) Okugawa T, Ikuta Y, Takahashi Y, et al:Induction of HLA-A24 restricted CTL by a novel human HER2 derived peptide homologous to the murine tumor rejection antigen in ovarian cancer patients and normal individuals. Eur J Immunol 30:3338-3346, 2000.

• 8) Ikuta Y, Katayama N, Wang L, et al:Presentation of amajor histocompatibility complex class l-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex:implications for a polyvalent immuno-cell therapy. Blood 99:3717-3724, 2002.

• 9) Gu XG, Schmitt M, Hiasa A, et al:A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 58:3385-3390, 1998.
  pubmed

8. 放射線療法

P.377 掲載の参考文献

• 1) Schray MF, Ox RS, Martinez A:Lower abdominal radiotherapy for stage I, II and selected III epithelial ovarian canacer:20 years, experience. Gynecol Oncol 15:78-87, 1983.

• 2) Dembo AJ:The ovary. Radiation Oncology(6th ed)(Moss WT&Cox JD ed), pp586-593, Mosby, St. Louis, 1989.

• 3) Smith JR, Rutledge FN, Delclos L:Postoperative treatment of early cancer of the ovary:A Randomized trail between postoperative irradiation and chemo-therapy. J Nat Cancer Inst 42:149-153, 1975.

• 4) Ovarian epitehlial cancer treatment. NCI PDQ 2005(http://www.caner.gov/cancerinfo/pdq/treatment/overianepithelial/healthprofessional/)

• 5) Lanciano R, et al:Update on the Role of Radiotherapy in Ovarian Cancer. Seminor in Oncology 25:361-371, 1998.

• 6) Fuks Z, Rizel S, Biran S:Chemotherapeutic and surgical induction of pathological complete remission nad whole abdominal irradiation for consolidation does not enhance the cure of stage III pvarian carcinoma. J Clin Oncol 6:509-516, 1988.

• 7) Young RC, et al:Adjuvant thrapy in stage I and stage II epithelial ovarian cancer:Results of two prospective randomized trials. N Engl J Med 322:1021-1027, 1990.

• 8) Firat S, Murray K, Erichson B:High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma:Long-term toxicity and outcome. Int J Radiat Oncol Bio Phys 57:201-207, 2003.

P.381 掲載の参考文献

• 1) Corn BW, Lanciano RM, Boente M, et al:Recurrent ovarian cancer:Effective radiotherapeutic palliation after chemotherapy failure. Cancer 74:2979, 1994.
  pubmed

• 2) May LE, Bellinson JL, Roland TA:Palliative benefit of radiation therapy in advanced cancer. Gynecol Oncol 37:408-411, 1990.

• 3) Ratanatharathorn V, Powers W, Moss W, et al:Bone Metastasis:Review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 44:1-18, 1999.
  pubmed

• 4) Coia LR, Hanks GE, Martz K, et al:Practice patterns of palliative care for the United States 1984-1985. Int J Radiat Oncol Biol Phys l4:1261-1269, 1988.

• 5) 谷川昇, 小島博之, 米虫敦, ほか:特集 経皮的椎体形成術5. 椎体腫瘍に対するIVR. IVR会誌 19:371-376, 2004.

• 6) Koyama M, Takizawa K, Kobayashi K, et al:Initial Experience of Percutaneous Vertebroplasty Using Single-plane C-arm Fluoroscopy for Guidance. Radiation Medicine 23:256-260, 2005.

• 7) Gaspar L, Scott C, Rotman M, et al:Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group brain trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
  pubmed

• 8) Bolgelt B, Gelbert R, Kramer S, et al:The palliation of brain metastases:final results of the two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9, 1980.

• 9) ガンマナイフ治療 症例を中心として, 小林達也編集. 名古屋大学出版会, 名古屋, 1998.

• 10) 林靖之, 柴田尚武:V臨床各論, 5転移性脳腫瘍. 直線加速器による定位放射線照射の理論と実際, 柴田尚武, 白土博樹, 平岡眞寛編集, pp132-162, 医学書院, 東京, 1999.

9. 卵巣癌検診

P.387 掲載の参考文献

• 1) http://www.ncc.go.jp/jp/kenshin/hyoka.html

• 2) http://www.mc.pref.osaka.jp/ocr/healthcheck/effectiveness.html

• 3) 小林浩:卵巣癌検診と腫瘍マーカー. 産婦人科の世界52(9):1247-1255, 2003.

• 4) Schwartz PE:Nongenetic screening of ovarian malignancies. Obstet Gynecol Clin North Am 28(4):637-651, 2001.
  pubmed

• 5) Menon U, Jacobs IJ:Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 12(1):39-42, 2000.
  pubmed

• 6) Alexander-Sefre F, Menon U, Jacobs IJ:Ovarian cancer screening. Hosp Med 63(4):210-213, 2002.
  pubmed

• 7) Modugno F:Ovarian Cancer and High-Risk Women Symposium Presenters. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 91(1):15-31, 2003.
  pubmed

• 8) Varras M:Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer. Clin Exp Obstet Gynecol 31(2):85-98, 2004.
  pubmed

• 9) Fung MF, Bryson P, Johnston M, et al:Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Screening postmenopausal women for ovarian cancer:asystematic review. J Obstet Gynaecol Can 26(8):717-728, 2004.

• 10) Tchabo NE, Liel MS, Kohn EC:Applying proteomics in clinical trials:assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics 5(3):141-148, 2005.
  pubmed

• 11) Guppy AE, Nathan PD, Rustin GJ:Epithelial ovarian cancer:areview of current management. Clin Oncol(R Coll Radiol) 17(6):399-411, 2005.

• 12) Tiffen J, Mahon SM:Ovarian cancer screening:are there any options? Clin J Oncol Nurs 9(3):369-372, 2005.
  pubmed

• 13) Anderiesz C, Quinn MA:screening for ovarian cancer. Med J Aust 16; 178(12):655-656, 2003.

• 14) Kauff ND, Hurley KE, Hensley ML, et al:Ovarian carcinoma screening in women at intermediate risk:impact on quality of life and need for invasive follow-up. Cancer 15; 104(2):314-320, 2005.

• 15) Jacobs IJ, Menon U:Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3(4):355-366, Epub 2004 Feb 516) Erzen M, Rakar S, Klancnik B, et al:Endometriosis-associated ovarian carcinoma(EAOC):an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 83(1):100-108, 2001.

• 17) Prefumo F, Todeschini F, Fulcheri E, et al:Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol 84(2):280-284, 2002.
  pubmed

10. 卵巣癌治療におけるインフォームド・コンセント

P.393 掲載の参考文献

• 1) L Elit C Charles, I Gold, et al:Women:s perceptions about treatment decision making for ovarian cancer. Gynaecol Oncol 88:89-95, 2003.

• 2) 池永満:患者の権利. 九州大学出版会, 1994.

• 3) Greenhalgh T, Haurwitz B, et al:Narrative Based Medicine:Dialogue and discourse in clinical practice. BMJ Books, London, 1998.

• 4) Baile WF, Kudelka AP, Beale EA, et al:Communication skills training in oncology. Cancer 86:887-897, 1997.

• 5) 大上俊彦, 下山直人:がん告知後のアフターケア. 日本臨床59(supp14):575. 579, 2001.

• 6) Aabo K, Adams M, Adnitt P, et al:Chemotherapy in advanced ovarian cancer:four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists:Group. Br J Cancer 78:1479-1487, 1998.
  pubmed

• 7) 田原克志:わが国の終末期医療の現状と今後の対応-「終末期医療に関する調査等検討会」報告書について. ホスピス緩和ケア白書2005. pp18-30,(財) 日本ホスピス.緩和ケア振興財団, 2005.

P.403 掲載の参考文献

• 1) 福田治彦, 新美三由起, 石塚直樹:米国SWOGに学ぶがん臨床試験の実践. 医学書院, 2004.

• 2) 渡辺亨, 勝俣範之, 安藤正志, ほか:がん診療レジデントマニュアル第3版. 国立がんセンター内科レジデント編, 医学書院, 2004.

• 3) Mcguire MJ, Hoskins WJ, Brady MF, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996

• 4) Piccart MJ, Bertelson K, James K, et al:Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:Thrce-Year Results. J Natl Cancer Inst 92(9):699-708, 2000.

• 5) Ozols RF, Bundy BN, Greer BE, et al:Phase III Trial carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer:AGynecologic Oncology Group Study. J Clin Oncol 21(17):3194-3200, 2003.

• 6) Armstrong DK, Bundy B, Wenzel L, et al:Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 200

P.411 掲載の参考文献

• 1) 卵巣がん治療ガイドライン. 日本婦人科腫瘍学会編, 金原出版, 2004.

• 2) Zanotti K, Belinson JL, Kennedy AW:Treatment of gynecologic cancer in pregnancy. Semin Oncol 27:686-698, 2000.
  pubmed

• 3) Brewer M, Gershenson DM, Herzog CE, et al:Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol l 7:2670-2675, 1999.

• 4) Morice P, Cammatte S, Wicart-Poque F, et al:Results of conservative management of epitherial malignant and borderline ovarian tumors. Hum Reprod Update 9:185-192, 2003.

• 5) Rahman MS, Al-Sibai MH, Rahman J, et al:Ovarian carcinoma associated with pregnancy. A review of g cases. Acta Obstet Gynecol Scand 81:260-264, 2002.

• 6) Sood AK, Shahin MS, Sorosky JI:Pacritaxel and Platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 83:599-600, 2001.

• 7) Sagae S, Sasaki H, Nishioka Y, et al:; Reproductive fucntion after treatment of malignant germ cell ovarian tumors. Mol Cell Endocrinol 202:117-121, 2003.

• 8) Ferrandina G, Distefano M, Testa A, et al:Management of an advanced ovarian cancer at 15 weeks of gestation:case report and literature review. Gynecl Oncol 97:693-696, 2005.
  pubmed

• 9) 柳光寛仁, 宮崎康二:腫瘍合併妊娠の取り扱い6. 悪性(低悪性) 卵. 巣腫瘍. 産と婦 68:622-631, 2001.

• 10) 菅井照夫, 田中俊誠, 佐藤博,ほか:婦人科疾患と関係のある腫瘍マーカー値の妊娠,分娩および産褥における変動について. 日産婦誌 43:145-151, 1991.

• 11) 筒井章夫:妊娠と卵巣腫瘍合併の取り扱いその2. 悪性卵巣腫瘍. 日産婦誌 44:N51-N54, 1992.

• 12) 高倉聡, 茂木真, 中島邦宣, ほか:Fetus in uteroで薬物動態をみながら癌化学療法を行い生児を得た卵巣悪性腫瘍合併妊娠の1例. 日産婦誌 53:491, 2001. 411

P.417 掲載の参考文献

• 1) 玉舎輝彦:産婦人科薬物療法のすべて. pp290, 金芳堂, 京都, 1996.

• 2) 玉舎輝彦:抗腫瘍療法と生殖機能. 周産期医学 32:1010-1013, 2002.

• 3) Mehta RR:Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 20:125-132, 1991.

• 4) 玉舎輝彦:排卵誘発の今後の展望. 産婦人科の世界 55:1263-1269, 2003.

• 5) Gosden RG:Low-temperature frozen banking of immature follicles and ovarian tissue. Reproductive medicine in the twenty first century, Healy DL, Kobace GT, McLachlan R, et al, ed, pp280-286, Boca Raton, New York, 2002.

• 6) Averette HE, Nguyen HN:The role of prophylactic oophorectomy in cancer prevention. Gyneco10nco1 55:S38-S41, 1995.

• 7) Jiang X, Morland S, Hitchcock A, et al:Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707-1712, 1998.
  pubmed

• 8) Erzen M, Rakar S, Klancar B, et al:Endometriosis-associated ovarian carcinomas(EAOC) ; an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 83:100-108, 2001.

• 9) Shoham Z:Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma:Where are we today? Fertil Steril 62:433-448, 1994.
  pubmed

• 10) Venn A, Watson L, Bruinsuma F, et al:Risk of cancer after use of fertility drugs with in-vitro fertilization. Lancet 354:1586-1590, 1990.

P.421 掲載の参考文献

• 1) Varma R, Rollason T, Gupta JK, et al:Endometriosis and the neoplastic process. Reproduction 127:293-304, 2004.
  pubmed

• 2) Sampson JA:Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg 10:1-72, 1925.

• 3) Perfulno F, Todeschini F, Fulcheri E, et al:Epitherial abnormality in cystic ovarian endometriosis. Gynecol Oncol 84(2):280-284, 2002.

• 4) Ness RB, Cramer DW, Goodman MT, et al:Infertility, fertility drugs, and ovarian cancer:apooled analysis of case-control studies. Am J Epidemiol 155:217-224, 2003.

• 5) Ness RB, Crisso JA, Cottreau C, et al:Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111-117, 2000.

• 6) Brinton LA, Lamb EJ, Moghissi KS, et al:Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 82:405-414, 2004.
  pubmed

• 7) Brinton L, Gridley G, Persson I, et al:Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176:572-579, 1997. 8) Duczman L, Ballweg ML:Endometriosis and cancer:what is the connection? Endometriosis Assoc Newsl 20:1-16, 1999.

• 9) 小林浩:子宮内膜症の悪性化. 産科と婦人科 72(3):366-373, 2005.
  Medical*Online

• 10) Janet E, James R, Carol A, et al:Postmenopausal Cancer Risk after Self-Reported Endometriosis Diagnosis in the Iowa Women:s Health Study. Cancer 94(5):1612-1618, 2002.

• 11) Linda G, Lee K:Endometriosis. The Lancet 364:1789-1799, 2004.

• 12) Fukunaga M, Nomura K, Ishikawa E, et al:0varian atypical endometriosis:its close association with malignant epithelial tumours. Histopathology 30:249-255, 1997.
  pubmed

• 13) 小畑孝四郎:卵巣子宮内膜症の癌化とその治療. 日産婦誌 55:890-902, 2003.

• 14) Sainz dlC, Izquierdo M, Canamero M, et al:Increased prevalence of p530verexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol 11 3:87-93, 2004.

• 15) Toki T, Nakayama K:Proliferative activity and genetic alterations in TP53 in endometriosis. Gynecol 0bstet lnvest 50 Suppl 1:33-38, 2000.

• 16) Martini M, Ciccarone M, Garganese G, et al:Possible involvement of hMLHI, p161NK4a, and PTEN in the malignant transformation of endometriosis. Int J Cancer 1O2:398-406, 2002.

• 17) Berchuck A, Schildkraut JM, Wenham RM, et al:Progesterone receptor promoter+331 A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 13:2141-2147, 2004.

• 18) Amemiya S, Sekizawa A, Otsuka J, et al:Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. Int J Gynaecol Obstet 86:371-376, 2004.
  pubmed

• 19) Otsuka J, Okuda T, Sekizawa A, et al:K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med Electron Microsc 37:188-192, 2004.
  pubmed

• 20) 小畑孝四郎, 椎名昌美, 小池英爾:卵巣子宮内膜症の癌化とその治療. 産婦人科治療 90(6):1023-1027, 2005.
  Medical*Online

• 21) Van Gorp T, Amant F, Neven P, et al:Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 18:349-371, 2004.
  pubmed

• 22) McMeekin DS, Burger RA, Manetta A, et al:Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 59:81-86, 1995.
  pubmed

• 23) DePriest PD, Banks ER, Powell DE, et al:Endomeioid carcinoma of the ovary and endometriosis. Gynecol Oncol 47:71-75, 1992.
  pubmed

• 24) 竹原和宏, 藤井恒夫, 佐治文隆, ほか:子宮内膜症に合併する卵巣明細胞腺癌の検討. 日本婦人科腫瘍学会雑誌 23(1):51-56, 2005.

• 25) Louise A, Lori C, Mark E, et al:Relationship of Benign Gynecologic Disease to Subsequent Risk of Ovarian and Uterine Tumors. Cancer Epidemiol Biomarkers Prev 14(12):2929-2934, 2005.

• 26) 木下孝史, 日浦昌道, 大亀真一, ほか:卵巣癌における子宮内膜症合併の臨床的意義について. 日本婦人科腫瘍学会雑誌 23(1):57-66, 2005.

• 27) 島田宗昭, 大石徹朗, 金森康展, ほか:卵巣チョコレート嚢胞から悪性腫瘍除外診断の試み. 日本婦人科腫瘍学会雑誌 23(1):67-71, 2005.

11. チーム医療と緩和ケア

P.427 掲載の参考文献

• 1) 細田満和子:「チーム医療」の理念と現実. pp32-35, 日本看護協会出版会, 東京, 2003.

• 2) Siegler EL, Whitney FW:What is collaboration In:Nurse-Physician Collaboration, Care of Adults and the Elderly, Siegler EL and Whitney FW, eds., pp3-10, Springer Publishing Company, New York, 1994.

• 3) 片岡明美, 大野真司, 大島彰:チーム医療-患者と家族が求める医療遂行のためのシステム構築-, 乳癌の臨床19:441-447, 2004.

• 4) 渡辺博, 稲葉憲之:医療者間, 患者とのコミュニケーション, チーム医療. 日産婦誌57:493-497, 2005.

• 5) 高山智子:チーム医療における患者医療者関係. チーム医療論, 鷹野和美編, pp11-24, 医歯薬出版, 東京, 2002.

• 6) 斎藤清二, 岸本寛史:ナラティブ.ベイスト.メディスンの実践. 金剛出版, 東京, 2003.

P.431 掲載の参考文献

• 1) 恒藤 暁:末期癌患者の特徴.最新緩和医療学第1版, pp18, 最新医学社, 大阪, 1999.

• 2) 堀泰祐,明神徹郎,井上卓也:卵巣癌患者に対する緩和ケアの実際.産婦人科の実際53:87-93,2004.

• 3) 堀泰祐:腸管閉塞.一般病棟における緩和ケアマニュアル, 第1版, 小川道雄編, pp146-149, ヘルス出版, 東京, 2005.

• 4) 堀 泰祐, 大垣和久:病名告知におけるケース.カンファレンスの実際〜受容良好例・不良例の検討.一般病棟・病院における緩和ケア・癒しの看護(上巻), pp251-270, 日総研, 東京, 1996.

P.435 掲載の参考文献

• 1) Fitch MI:Psychosocial management of patients with recurrent ovarian cancer:treating the whole patient to improve quality of life. Semin Oncol Nurs 3 Suppl 1:40-53, 2003.

• 2) まつばらけい:婦人科がん患者になるということ. 助産婦雑誌 55:937-945, 2001.

• 3) 保坂隆:緩和医療の実際-精神的ケアがんと心-サイコオンコロジー. 臨床外科 55:1095-1099, 2000.

• 4) 岡本泰昌:婦人科腫瘍. サイコオンコロジー(山脇 成人監, 内富庸介編), pp95-115, 診療新社, 大阪, 1997.

• 5) Derogatis LR, Morrow GR, Fetting D, et al:The prevalence of psychiatric disorders among cancer patients. JAMA 249:751-757, 1983.

• 6) Evans DL, McCartney CF, Nemeroff CB, et al:Depression in women treated for gynecologic cancer:clinical and neuroendocrine assessment. Am J Psychiatry 143:447-452, 1986. 435

• 7) Cain EN, Kohorn EI, Quinlan DM, et al:Psychosocial reactions to the diagnosis of gynecologic cancer. Obst Gynec 62:635-641, 1983.

• 8) McCartney CF, Larson DB, Wada CY, et al:Effect of psychiatric liaison on consultation rates and reasons for consult in gynecologic oncology. J Psychosomt Obst Gynaecol 5:253-261, 1986.

• 9) 明智龍男:がん患者の抑うつへのアプローチ. リエゾン精神医学とその治療学(山脇成人編), pp67-77, 東京, 2003.

• 10) 坂田三允:がん患者のメンタルケア. 助産婦雑誌 55:974-979, 2001.

• 11) 高橋都:がん患者のセクシュアリティ. ターミナルケア 14:349-355, 2004.

• 12) Annon JS:The PLISSIT model:a proposed conceptual scheme for the behavioral treatment of sexual problems. J Sex Ed Ther 2:1-15, 1976.

• 13) Schover LR, Evans RB, Von Eschenbach AC:Sexual rehabilitation in a cancer center:diagnosis and outcome of 384 consultations. Arch Sex Behav 16:445-461, 1987.

• 14) 斉藤和男, 鈴木康太郎, 野口和美, ほか:がん患者に対する精子凍結保存の意義-アンケート調査結果より. 日本泌尿器科学会雑誌 194:129, 2003.

• 15) 渡邊知映:がん治療後に子供を持つということ. ターミナルケア 14:377-381, 2004,

• 16) Auchincloss SS, McCartney CF:Gynecologic Cancer. In Holland JC(eds):Hand dbook of Psycho-Oncology, pp981-993, 0xford University Press, New York, 1998.

• 17) 高橋都:がん当事者とセルフヘルプ・グループ. ターミナルケア 13:357-360, 2003.

P.441 掲載の参考文献

• 1) Schug S, Zech D, Dorr U:Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 5:27-32, 1990.
  pubmed

• 2) Hippisley-Cox J, Coupland C:Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs:Population based nested case-control analysis. BMJ 330:1366-1369, 2005.
  pubmed

• 3) Chandrasekharan NV, Dai H, Roos KLT, et al:COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs:Cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926-13931, 2002.
  pubmed

• 4) 的場元弘:非オピオイド(アスピリン, NSAID) の使い方. 厚生省平成9年度がん患者の緩和ケアに関する講習会資料, pp8-12, 1998.

• 5) 的場元弘:がん性疼痛とNSAIDs. 効果を十分に引き出すための理解. ターミナルケア 6:5-10, 1996.

• 6) 高橋秀徳, 下山直人:オピオイドローテーションによる疼痛コントロール. 薬局 56:1387-1392, 2005.
  Medical*Online

• 7) 柏木哲夫, 恒藤暁, 池永昌之, ほか:鎮痛薬の種類と使用法. 緩和ケアマニュアル, 淀川キリスト教病院編, pp37-40, 最新医学社, 大阪, 1992,

• 8) 下山直人, 村上敏史, 高橋秀徳, ほか:オピオイドスイッチングにおけるオキシコドン徐放剤の役割. がん患者と対症療法 16:33-38, 2005.

• 9) 柏木哲夫, 恒籐暁, 池永昌之, ほか:モルヒネの使用法. 緩和ケアマニュアル, 淀川キリスト教病院(編), pp41-55, 最新医学社, 大阪, 1992.

• 10) 有賀悦子:強オピオイド(モルヒネ) の使い方. 厚生省平成9年度がん患者の緩和ケアに関する講習会資料, PP33-47, 1998.

• 11) 有田英子, 齋藤勇一郎, 鈴木正寛, ほか:わが国でのオピオイドローテーションにおける役割と問題点. 緩和医療学 7:23-31, 2005.
  Medical*Online

• 12) 恒藤暁:がん性疾痛(その3). 最新医学 52:1783-1791, 1997.

• 13) 堀泰祐, 明神徹郎, 井上卓也:卵巣癌患者に対する緩和ケアの実際. 産婦人科の実際 53:87-93, 2004.

• 14) 合田由起子:ケタミンを使った鎮痛治療とは. ターミナルケア7suppl:130-135, 1997.

• 15) 的場元弘:抗けいれん薬と抗うつ薬の使い方. ターミナルケア7suppl.:117-124, 1997.

• 16) 池永昌之, 恒藤暁:コルチコステロイドを使いこなす. ターミナルケア7suppl.:302-312, 1997.

• 17) 志真泰夫:消化管閉塞に対応するには. ターミナルケア7suppl.:178-181, 1997.

• 18) Ichinose Y, Hara N, Ohta M, et al:Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer; In vitro experiments and preliminary clinical results. J Thorac Cardiovasc Surg 105:1041-1046, 1993.
  pubmed

• 19) 斎藤龍雄:呼吸困難の薬物療法とは. ターミナルケア7suppl:230-234, 1997.

P.446 掲載の参考文献

• 1) 厚生省:患者誤認事故防発方策に関する検討会報告書. 1999年.

• 2) 厚生労働省医療安全対策検討会議(編):医療安全推進総合対策〜医療事故を未然に防止するために. じほう, 2002年.

• 3) Heinrich HW:Industrial Accident Prevention-A Scientific Approach. McGraw-Hill, New York, 1931.

• 4) 川村治子:看護のヒヤリ・ハット事例の分析〜与薬(注射) エラー発生要因の分析を中心として〜. 厚生省「医療のリスクマネジメントシステム構築に関する研究」報告書, 1999年.

• 5) 福井英二, 山口聡, 竹森正幸, ほか:がん化学療法とリスクマネージメント. 臨床婦人科産科 58:177-183, 2004.

• 6) 大坪健司, 椎木芳和:セーフティマネジメントを指向した注射処方オーダリングシステム. 月刊薬事 47:573-579, 2005.

12. 病期分類および治療判定

P.452 掲載の参考文献

• 1) 卵巣腫瘍取扱い規約 第2部 改訂 第2版. 金原出版社, 1997.

• 2) Onda T, et al:Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. Cancer 78:803-808, 1996.
  pubmed

• 3) Carnino F, Fuda G, Ciccone G, et al:Significance of lymph node sampling inepithelial carcinoma of the ovary. Gynecol Onol 65:467-472, 1997.

• 4) Trimbos JB, et al:Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 67:597-602, 1991.
  pubmed

• 5) Munnell EW:Is conservative therapy ever justified in stage I(Ia) cancer of the ovary? Am J Obstet Gynecol 103:641-653, 1969.

• 6) Kottmeier HL:The diagnosis and treatment of ovarian malignancies. Arq Patol 37:51-64, 1965.
  pubmed

P.462 掲載の参考文献

• 1) 粉川克司, 梅咲直彦:卵巣癌に対する化学療法. 産婦人科治療 90:1004-1012, 2005.
  Medical*Online

• 2) WHO Handbook for Reporting of Cancer Treatment. WHO, Geneva, 1979.

• 3) 日本癌治療学会:固形がん化学療法の直接効果判定基準. 日癌治誌 21:929-942, 1986.

• 4) 日本産科婦人科学会:婦人科がんの治療による組織学的効果判定基準. 卵巣腫瘍取扱い規約(改訂第2版第2部), pp59-68, 金原出版, 1997,

• 5) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 91:523-528, 1999.

• 6) 下山正徳, 福田治彦(訳):固形がんの治療効果判定のための新ガイドライン(RECISTガイドライン)-日本語訳JCOG版, Excerpta Medica, Hills Borough, 2002

• 7) 青木道子, 八重樫伸生:癌化学療法の新しい効果判定-RECISTについて. 産と婦 69:549-554, 2002.
  Medical*Online

• 8) 日本産科婦人科学会:婦人科がん化学療法の直接効果判定基準. 卵巣腫瘍取扱い規約(改訂第2版第2部), pp69-71, 全原出版, 1997.

• 9) Rustin GJ, Nelstrop AE, McClean P, et al:Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996.
  pubmed

• 10) Rustin GJ:Use of CA 125 to assess response to new agnts in ovarian cancer trials. J Clin Oncol 21:187-193, 2003.

• 11) Rustin GJ, Nelstrop AE, Tuxen MK, et al:Defining progression of ovarian carcinoma during follow-up according to CA 125:ANorth Thames Ovary Group Study. Ann Oncol 7:361-364, 1996.

• 12) 島田宗昭, 板持宏明, 紀川純三:卵巣がん治療の効果判定, 再発予知と腫瘍マーカー. 臨婦産59:1370-1373, 2005.

13. 特別企画

P.469 掲載の参考文献

• 1) 藤原久也, 水之江知哉, 上田克憲, ほか:婦人科がん手術例に対するクリニカルパスの検討. 広島医学 57:826-828, 2004.

• 2) 向後麻里, 岡井崇, 木内祐二, ほか:卵巣癌 carboplatin/paclitaxel療法に対する科学的根拠に基づいたクリニカル.パスの作成. 医療薬学 30:394-400, 2004.
  Medical*Online

• 3) 久布白兼行, 藤井多久磨, 野澤志朗:医療の安全管理とヒューマンファクター婦人科病棟における薬剤投与. 日本外科系連合学会誌 28:431, 2003.

P.473 掲載の参考文献

• 1) 宇田川康博, 八重樫伸生, 鈴木光明, 葛谷和夫,杉山徹, ほか:卵巣がん治療ガイドライン-2004年版-. 日本婦人科腫瘍学会編, pp1-83, 金原出版, 東京, 2004.

P.476 掲載の参考文献

• 1) Omura G, et al:A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57:1725-1730, 1986,

• 2) West RJ, Zweig SF:Meta-analysis of chemotherapy regimens for ovarian carcinoma; a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol 18:343-348, 1997.
  pubmed

• 3) McGuire WP, Hoskins WJ, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 334:1-6, 1996.

• 4) Piccart MJ, et al:Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:three-year results. J Natl Cancer Inst 92:699-708, 2000.
  pubmed

• 5) Ozols RF, Bundy BN, et al:Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer; A gynecologic oncology group study. J Clin Oncol 21:156-159, 2003.

P.480 掲載の参考文献

• 1) 川渕孝一:わかりやすい医療経済学. 日本看護協会出版社.

• 2) Max W, Rice DP, Sung HY, et al:The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol 88(2):96-103. 2003.
  pubmed

• 3) Etzioni R, Urban N, Baker M:Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol 49(1):95-103, 1996.
  pubmed

• 4) Szucs TD, Wyss P, Dedes KJ:Cost-effectiveness studies in ovarian cancer. Int J Gynecol Cancer 13 Suppl 2:212-219, 2003.

• 5) Menon U, Jacobs IJ:Ovarian cancer screening in the general population:current status. Int J Gynecol Cancer II Suppl 1:3-6, 2001.

• 6) Jacobs IJ, Menon U:Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3(4):355-366, 2004.
  pubmed

• 7) van Nagell JR Jr, DePriest PD, Reedy MB, et al:The efficacy of transvaginal sonographic screening in a symptomatic women at risk for ovarian cancer. Gynecol Oncol 77(3):350-356, 2000.

• 8) Fishman DA, Cohen LS:Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma? Gynecol Onco177(3):347-349, 2000.
  pubmed

• 9) Chu CS, Rubin SC:Related Articles, Links Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 16, 2005.

• 10) Buys SS, Partridge E, Greene MH, et al:PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian(PLCO) cancer screening trial:findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193(5):1630-1639, 2005.

• 11) McGuire W, Neugut AI, Arikian S, et al:Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 15(2):640-645, 1997.
  pubmed

• 12) Berger K, Fischer T, Szucs TD:Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer 34(12):1894-1901, 1998.
  pubmed

• 13) Parmar MK, Ledermann JA, Colombo N, et al:ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer:the ICON4/AGO-OVAR-2. 2 trial. Lancet 361(9375):2099-2106, 2003.
  pubmed

• 14) Wheatley K, Gray R:ICON4/AGO-OVAR-2. 2:questions about trial design, cost-effectiveness, and clinical benefit. Lancet 362(9392):1333, 2003.
  pubmed

• 15) Dranitsaris G, Elia-Pacitti J, Cottrell W:Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmaco economics 22(6):375-387, 2004.

P.487 掲載の参考文献

• 1) Prat J, Ribe A, Gallardo A:Hereditary ovarian cancer. Hum Pathol 36:861-870, 2005.
  pubmed

• 2) Liu Y, Ganesan TS:Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction 123:341-353, 2002.
  pubmed

• 3) Sekine M, Nagata H, Tsuji S, et al:Japanese Familial Ovarian Cancer Study Group. Mutational analysis of BRCAl and BRCA2 and clinicopathologic analysis of ovarian cancer in 820varian cancer families:two common founder mutations of BRCA l in Japanese population. Clin Cancer Res lO:3144-3150, 2001.

• 4) Schmeler KM, Lynch HT, Chen LM, et al:Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-269, 2006.
  pubmed

• 5) 家族性腫瘍における遺伝子診断の研究とこれを応用した診療に関するガイドライン. http://www.k3.dion.ne.jp/%7Ejsft/guid.htm, 日本家族性腫瘍学会HP.

• 6) The American Society of Clinical 0ncology Position on Genetic Testing(Garber JE, et al). Cancer 632-634, 1997. http://WWW.ASCO.org/ac/1,1003,_12-002151,00.asp(改変)

• 7) Miki Y, Swensen J, Shattuck-Eidens D, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI. Science 266:66-71, 1994.

• 8) Yoshida K, Miki Y:Role of BRCAI and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866-871, 2004.

• 9) Wang C, Fan S, Li Z, et al:Cyclin D l antagonizes BRCAl repression of estrogen receptor alpha activity. Cancer Res 65:6557-6567, 2005.

• 10) Wooster R, Bignell G, Lancaster J, et al:Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995.
  pubmed

• 11) Kirchhoff T, Kauff ND, Mitra N, et al:BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 1O:2918-2921, 2004.

• 12) Lynch HT, Deters CA, Snyder CL, et al:BRCA I and pancreatic cancer:pedigree findings and their causal relationships. Cancer Genet Cytogenet 1 58:119-125, 2005.

• 13) 酒寄真人, 千葉奈津子, 河原正典, ほか:家族性乳癌の遺伝子検査にかかわる問題点. 家族性腫瘍 6:7-11, 2006.

• 14) 平原史樹:遺伝カウンセリング. 日産婦誌 58:N32-37, 2006.

• 15) 横山士郎, 小路滋, 下田泰裕, ほか:臨床検査としてのBRCA遺伝子検査. 家族性腫瘍 6:4-6, 2006.
  Medical*Online

• 16) 遺伝学的検査に関するガイドライン(2003年8月)遺伝医学関連の学会等(10学会および研究会) www.kuhp.kyoto-u.ac.jp/idennet/idensoudan/guideline/exam.html

• 17) ヒトゲノム・遺伝子解析研究に関する倫理指針. 2001年3月, 2004.年3月改変. http://www.mext.go.jp/a_menu/shinkou/seimei/genomeshishin/05062701.htm

• 18) Arai M, Utsunomiya J, Miki Y:Familial breast and ovarian cancers. Int J Clin Oncol 9:270-282, 2004.
  pubmed

• 19) Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al:Presymptomatic DNA testing and prophylactic surgery in families with a BRCAl or BRCA2 mutation. Lancet 355:2015-2020, 2000.
  pubmed

• 20) Lobb E, Meiser B:Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer. Lancet 363:1841-1842, 2004.

• 21) Finch A, Shaw P, Rosen B, et al:Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCAI and BRCA2 carriers. Gynecol Oncol 100:58-64, 2006.

• 22) 田村智英子:家族性腫瘍の若年者診断. 家族性腫瘍 4:6-9, 2004.
  Medical*Online

P.495 掲載の参考文献

• 1) Petricoin III EF, Ardekani AM, Hitt BA, et al:Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002.

• 2) 菊池義公, 斉藤賢治:プロテオミクスと治療の個別化. 産科と婦人科 73:1129-1135, 2006.
  Medical*Online

• 3) Ye B, Cramer DW, Skates SJ, et al:Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer:identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9:2904-2911, 2003.
  pubmed

• 4) Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al:Ovarian cancer mrker of 11. 7 kDa detected by proteomics is a serum amyloid Al. Proteomics 5:3790-3797, 2005.

• 5) Zhang Z, Bast RC, Yu Y, et al:Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890, 2004.
  pubmed

• 6) Kozak KR, Amneus MW, Pusey SM, et al:Identification of biomarkers for ovarian cancer using strong anion-exchange Protein Chips:Potential use in diagnosis and prognosis. PNAS 1OO:12343-12348, 2003.

• 7) Kozak KR, Su F, Whitelegge JP, et al:Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5:4589-4596, 2005.
  pubmed

• 8) Ye B, Skates S, Mok SC, et al:Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12:432-441, 2006.
  pubmed

• 9) Britten RA, Hardy C, Vlahou A, et al:Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistence in human ovarian cancer cells. Oncol Rep 14:1323-1330, 2005.
  pubmed

• 10) Zhu K, Fukusawa I, Fujinoki M, et al:Profiling of proteins associated with cisplatin resistence in ovarian cancer cells. Int J Gynecol 0ncol 15:747-754, 2005

P.498 掲載の参考文献

• 1) 日本婦人科腫瘍学会/編:2004年版卵巣がん治療ガイドライン, p22-23, 金原出版, 2004.

P.502 掲載の参考文献

• 1) 中島久良:卵巣腫瘍捺印細胞診. 婦人科細胞診の実際, 柏村正道編, pp89-103, 永井書店, 大阪, 1998.

• 2) 井浦俊彦, 伊藤正孝, 藤井亮太, ほか:悪性卵巣腫瘍のホルモン産生. 産婦人科の実際 43:1409-1413, 1994.

• 3) Motoyama T, Katayama Y, Watanabe H, et al:Functioning ovarian carcinoids induce severe constipation. Cancer 70:513-518, 1992.
  pubmed

• 4) Broadus AE, Mangin M, Ikeda K, et al:Humoral hypercalcemia of cancer; Identification of a novel parathyroid hormone-like peptide. N Engl J Med 319:556-563, 1988.
  pubmed

• 5) Kitazawa R, Kitazawa S, Matui T, et al:In situ detection of parathyroid hormone-related protein in ovarian clear cell carcinoma. Hum Pathol 28:379-382, 1997.
  pubmed

• 6) 斉藤俊章:ホルモン細胞診. 婦人科細胞診の実際, 柏村正道編, ppl27-136, 永井書店, 大阪, 1998.

• 7) 山片重房, 山本久美夫, 山本啓司, ほか:上皮性卵巣腫瘍のエストロゲン産生能に関する研究. 日本産科婦人科学会雑誌 41:1761-1768, 1989.

• 8) Scully RE:Tumor of the ovary and maldeveloped gonad. AFIP, Washinton DC, 1979.

• 9) Takayama K, Sasano H, Fukaya T, et al:Immunohisto-chemical localization of Ad4-binding protein with correlation to steroidgenetic enzyme expression in cycling human ovaries and sex cord stromal tumors. J Clin Endocrin Metab 80:2815-2821, 1995

P.506 掲載の参考文献

• 1) 工藤隆一, 石岡伸一, 寒河江悟:卵巣癌の治療. 外科治療-概論-. 口本臨床 62:522-526, 2004.

• 2) 山田秀和, 杉山徹:卵巣癌の治療. 化学療法-概論-. 日本臨床 62:540-545, 2004.
  Medical*Online

• 3) McGuireWP, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovaian cancer. N Engl J Med 334(1):1-6, 1996.

• 4) Bast RC Jr, Feeney M, Lazarus H, et al:Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin lnvest 68:1331-1337, 1981.

• 5) Jacobs I, Bast RC Jr:The CAI25 tumor-associated antigen. A review of the literature. Hum Reprod 4:1-12, 1989.

• 6) Koprowski H, Steplewski Z, Mitchell K, et al:Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957-972, 1979.
  pubmed

• 7) Duffy MJ:Carcinoma antigen as a marker for colorectal cancer:Is it clinically useful? Clin. Chemistry 47:4624-4630, 2001.

• 8) Rustin GJ, Nelstrop AE, Bentzen SM, et al:Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 10:21-27, 1999.
  pubmed

• 9) Rustin GJ, Marples M, Nelstrop AE, et al:Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol l9:4054-4057, 2001.

• 10) Wilder JL, Pavlik E, Straughn JM, et al:Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer:a preliminary investigation. Gynecol Oncol 89:233-235, 2003.
  pubmed

• 11) Nishiomura H, Tashiro M, Hamaguchi K, et al:Significance of the serum CAI25 level in recurrent ovarian cancer. Asia Oceania J Obstet Gynaecol 18:37-43, 1998.

• 12) 薬師寺道明, 片岡明生:卵巣癌の腫瘍マーカー. 図説産婦人科VIEW 18:174-179, 1999.

• 13) Sagae S, Ishioka S, Terasawa K, et al:Early detection of the recurrence of ovarian cancer with CA125 monitoring. J Gynecol Techniques 3:127-131, 1997.

• 14) Eisenhauer EA, Vermorken JB, van Glabbeke M:Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer:amultivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997.

• 15) Duffy MJ, Bonfrer JM, Kulpa J, et al:CAI25 in ovarian cancer:European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15:679-691, 2005.